[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1651
1. Yong RL, Kavanagh EC, Fenton D, Dorovini-Zis K, Heran MK, Haw CS: Midline cerebellar medulloblastoma in a seventy-one-year-old patient. Can J Neurol Sci; 2006 Feb;33(1):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Medulloblastoma is the most common malignant central nervous system tumour in children but, in contrast, quite rare in adults.
  • RESULTS: Histological examination showed a densely cellular neoplasm composed of small cells with a tendency towards neuroblastic rosette formation.
  • CONCLUSION: Adult medulloblastoma should be considered in the differential diagnosis of a partially calcified hyperattenuating mass within the fourth ventricle.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Aged. Brain Neoplasms / pathology. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Fourth Ventricle / pathology. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Phosphopyruvate Hydratase / metabolism. Synaptophysin / metabolism. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583731.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


2. Karabekir HS, Balci C, Tokyol C: Primary spinal anaplastic ganglioglioma. Pediatr Neurosurg; 2006;42(6):374-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas of the spinal cord are very unusual and the anaplastic variant of these tumors is extremely rare.
  • In spinal anaplastic gangliogliomas, malignant changes (hypercellularity, vascular proliferation, necrosis, high numbers of mitotic figures) are typically evident in the glial element of the tumor.
  • Gangliogliomas can arise in any part of the central nervous system and the features of adult and pediatric cases differ significantly.
  • The tumor was partially resected with an ultrasonic aspirator, but the patient's neurological status deteriorated as a result and adjuvant radiotherapy did not resolve the deficit.
  • [MeSH-major] Ganglioglioma / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Anaplastic Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17047418.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


3. Li Q, Shang H, Zhou D, Liu R, He L, Zheng H: Repeated embolism and multiple aneurysms: central nervous system manifestations of cardiac myxoma. Eur J Neurol; 2008 Dec;15(12):e112-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated embolism and multiple aneurysms: central nervous system manifestations of cardiac myxoma.
  • [MeSH-major] Heart Neoplasms / complications. Intracranial Aneurysm / diagnosis. Intracranial Aneurysm / etiology. Intracranial Embolism / diagnosis. Intracranial Embolism / etiology. Myxoma / complications
  • [MeSH-minor] Adult. Atrial Appendage / pathology. Atrial Appendage / physiopathology. Brain / blood supply. Brain / pathology. Brain / physiopathology. Brain Infarction / etiology. Brain Infarction / pathology. Brain Infarction / physiopathology. Brain Ischemia / etiology. Brain Ischemia / pathology. Brain Ischemia / physiopathology. Cerebral Angiography. Cerebral Arteries / pathology. Cerebral Arteries / physiopathology. Cerebral Arteries / radiography. Dysarthria / etiology. Female. Hemiplegia / etiology. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Thoracotomy. Vertigo / etiology

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Neurol. 2008 Dec;15(12):e110-1 [19049533.001]
  • (PMID = 19049534.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Kita T, Hayashi K, Yamamoto M, Kawauchi T, Sakata I, Iwasaki Y, Kosuda S: Does supplementation of contrast MR imaging with thallium-201 brain SPECT improve differentiation between benign and malignant ring-like contrast-enhanced cerebral lesions? Ann Nucl Med; 2007 Jul;21(5):251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final diagnoses were six glioblastomas, two cerebral metastases from lung cancer, and one each of abscess, resolving hematoma, primary central nervous system lymphoma, toxoplasmosis, and radiation necrosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / diagnosis. Brain Neoplasms / radionuclide imaging. Female. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging / methods. Male. Middle Aged. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634842.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Thallium Radioisotopes
  •  go-up   go-down


5. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis


6. Molcanyi M, Riess P, Haj-Yasein NN, Bentz K, Loehr M, Kuchta J, Zivcak J, Stenzel W, Miletic H, Hescheler J, Neugebauer E, Hampl JA, Ernestus RI, Schafer U: Developmental potential of the murine embryonic stem cells transplanted into the healthy rat brain--novel insights into tumorigenesis. Cell Physiol Biochem; 2009;24(1-2):87-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although engraftment of undifferentiated pluripotent embryonic stem cells (ESCs) into the injured central nervous system (CNS) may lead to targeted cell replacement of lost/damaged cells, sustained proliferative activity combined with uncontrolled differentiation of implanted cells presents a risk of tumor formation.
  • However, xenotransplantation (e.g., mouse to rat) without pre-differentiation, lead to the development of healthy neuronal cells, in absence of tumor formation, suggesting that tumor-suppressive effects of host tissue on engrafted ESCs may play a role in transplant tumorigenesis.
  • We critically investigated tumorigenesis and possible mechanisms of anticipated tumor-suppressive effect under conditions analogous to previously published studies.
  • Xenotransplantation of D-3 murine ESCs into uninjured adult rat brains lacking any preliminary inflammatory potential was found to lead to tumor formation in 5 out of 8 of animals within 2 weeks postimplantation.
  • Tumor-suppressive effects, reflected by Erdo et. al could possibly be ascribed to immunomodulatory activity of macrophages scavenging the tumorigenic fraction of the implanted cells.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Embryonic Stem Cells / transplantation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19590196.001).
  • [ISSN] 1421-9778
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Magrassi L, Bongetta D, Bianchini S, Berardesca M, Arienta C: Central and peripheral components of writing critically depend on a defined area of the dominant superior parietal gyrus. Brain Res; 2010 Jul 30;1346:145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central and peripheral components of writing critically depend on a defined area of the dominant superior parietal gyrus.
  • Classical neuropsychological models of writing separate central (linguistic) processes common to oral spelling, writing and typing from peripheral (motor) processes that are modality specific.
  • Moreover, our findings also suggest that some of the central processes specific for typing and handwriting converge with motor processes at least in the limited portion of the superior parietal gyrus we mapped in our patients.
  • [MeSH-major] Agraphia / physiopathology. Central Nervous System / physiology. Handwriting. Parietal Lobe / physiology. Peripheral Nervous System / physiology
  • [MeSH-minor] Adult. Aged, 80 and over. Astrocytoma / surgery. Brain Mapping. Brain Neoplasms / surgery. Craniotomy. Electroencephalography. Female. Frontal Lobe / physiology. Humans. Magnetic Resonance Imaging. Male. Psycholinguistics. Reading

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20580692.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Filatova LV, Gershanovich ML: [Clinical features and combined treatment of the central nervous system in Hodgkin's disease]. Vopr Onkol; 2008;54(5):643-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and combined treatment of the central nervous system in Hodgkin's disease].
  • Tumor-induced specific changes in the brain and spinal cord compression had worse prognosis and median of survival from time of tumor detection was approx. 12 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Hodgkin Disease / complications. Hodgkin Disease / therapy. Spinal Cord Compression / etiology. Spinal Cord Compression / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Child. Female. Humans. Lomustine / administration & dosage. Male. Methylnitrosourea / administration & dosage. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069483.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 684-93-5 / Methylnitrosourea; 7BRF0Z81KG / Lomustine; U68WG3173Y / Carmustine
  •  go-up   go-down


9. Shiels MS, Cole SR, Chmiel JS, Margolick J, Martinson J, Zhang ZF, Jacobson LP: A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men. J Clin Epidemiol; 2010 Apr;63(4):459-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men.
  • OBJECTIVE: To compare three ad hoc methods to estimate the marginal hazard of incident cancer acquired immune deficiency syndrome (AIDS) in a highly active antiretroviral therapy (1996-2006) relative to a monotherapy/combination therapy (1990-1996) calendar period, accounting for other AIDS events and deaths as competing risks.
  • STUDY DESIGN AND SETTING: Among 1,911 human immunodeficiency virus (HIV)-positive men from the Multicenter AIDS Cohort Study, 228 developed cancer AIDS and 745 developed competing risks in 14,202 person-years from 1990 to 2006.
  • Method 1 censored competing risks at the time they occurred, method 2 excluded competing risks, and method 3 censored competing risks at the date of analysis.
  • RESULTS: The age, race, and infection duration adjusted hazard ratios (HRs) for cancer AIDS were similar for all methods (HR approximately 0.15).
  • We estimated bias and confidence interval coverage of each method with Monte Carlo simulation.
  • On average, across 24 scenarios, method 1 produced less-biased estimates than methods 2 or 3.
  • CONCLUSIONS: When competing risks are independent of the event of interest, only method 1 produced unbiased estimates of the marginal HR, although independence cannot be verified from the data.
  • When competing risks are dependent, method 1 generally produced the least-biased estimates of the marginal HR for the scenarios explored; however, alternative methods may be preferred.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):65-70 [10534148.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Biometrics. 2000 Sep;56(3):779-88 [10985216.001]
  • [Cites] Epidemiology. 2000 Sep;11(5):550-60 [10955408.001]
  • [Cites] AIDS. 2001 Feb 16;15(3):347-55 [11273215.001]
  • [Cites] Am J Epidemiol. 2001 Oct 1;154(7):675-81 [11581102.001]
  • [Cites] J Epidemiol Community Health. 2002 Feb;56(2):153-9 [11812817.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):81-7 [12048367.001]
  • [Cites] Int J Epidemiol. 2002 Oct;31(5):951-8 [12435766.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):22-9 [12853195.001]
  • [Cites] Am J Epidemiol. 2003 Oct 1;158(7):687-94 [14507605.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1267-74 [14575971.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):45-9 [15158046.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Jan;72(1):20-2 [1054494.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2127-39 [7846415.001]
  • [Cites] Biometrics. 1995 Jun;51(2):524-32 [7662841.001]
  • [Cites] Epidemiology. 1997 Jul;8(4):453-6 [9209864.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1497-503 [9809730.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1933-42 [10513653.001]
  • [Cites] Am J Epidemiol. 2005 Sep 1;162(5):479-86 [16076827.001]
  • [Cites] AIDS. 2005 Nov 18;19(17):2009-18 [16260908.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):975-82 [16207808.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):310-5 [16371516.001]
  • [Cites] AIDS. 2006 Mar 21;20(5):741-9 [16514305.001]
  • [Cites] Stat Med. 2006 Apr 30;25(8):1431-3; author reply 1433 [16572384.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):624-31 [16652037.001]
  • [Cites] Am J Epidemiol. 2007 Feb 15;165(4):464-72 [17116649.001]
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):911-8 [17267419.001]
  • [Cites] Stat Med. 2007 May 20;26(11):2389-430 [17031868.001]
  • [Cites] Am J Epidemiol. 2007 Jul 1;166(1):71-8 [17426038.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):520-9 [18677024.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):4027-34 [18711194.001]
  • [Cites] Pharm Stat. 2008 Jul-Sep;7(3):202-14 [17554753.001]
  • [Cites] Am J Epidemiol. 2009 May 1;169(9):1124-32 [19318615.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):485-90 [18614916.001]
  • (PMID = 19880284.001).
  • [ISSN] 1878-5921
  • [Journal-full-title] Journal of clinical epidemiology
  • [ISO-abbreviation] J Clin Epidemiol
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042-11; United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / U01 AI035041-17; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / U01 AI035040-16; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI035039-17; United States / NIAID NIH HHS / AI / AI037984-08; United States / NIAID NIH HHS / AI / AI035039-17; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / U01 AI037613-08; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / AI035043-17; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / U01 AI037984-08; United States / NCI NIH HHS / CA / T32 CA009314-28S3; United States / NIAID NIH HHS / AI / U01 AI035043-17; None / None / / M01 RR000722-23; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / AI037613-08; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCI NIH HHS / CA / T32 CA009314-27; United States / NCRR NIH HHS / RR / 5-MO1-RR-00722; United States / NCRR NIH HHS / RR / M01 RR000722-23; United States / NCI NIH HHS / CA / CA009314-28S3; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / T32 CA009314
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS157075; NLM/ PMC2837111
  •  go-up   go-down


10. Ganmaa D, Willett WC, Li TY, Feskanich D, van Dam RM, Lopez-Garcia E, Hunter DJ, Holmes MD: Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. Int J Cancer; 2008 May 1;122(9):2071-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up.
  • The relation between consumption of coffee, tea and caffeine and risk of breast cancer remains unsettled.
  • We examined data from a large, long-term cohort study to evaluate whether high intake of coffee and caffeine is associated with increased risk of breast cancer.
  • This was a prospective cohort study with 85,987 female participants in the Nurses' Health Study.
  • Consumption of coffee, tea and caffeine consumption was assessed in 1980, 1984, 1986, 1990, 1994, 1998 and the follow-up continued through 2002.
  • We documented 5,272 cases of invasive breast cancer during 1,715,230 person-years.
  • The multivariate relative risks (RRs) of breast cancer across categories of caffeinated coffee consumption were: 1.0 for <1 cup/month (reference category), 1.01 (95% confidence interval: 0.92-1.12) for 1 month to 4.9 week, 0.92 (0.84-1.01) for 5 week to 1.9 days, 0.93 (0.85-1.02) for 2-3.9 days, 0.92 (0.82-1.03) for >or=4 cups per day (p for trend = 0.14).
  • Intakes of tea and decaffeinated coffee were also not significantly associated with risk of breast cancer.
  • RRs (95% CI) for increasing quintiles of caffeine intake were 1.00, 0.98 (0.90-1.07), 0.92 (0.84-1.00), 0.94 (0.87-1.03) and 0.93 (0.85-1.01) (p for trend = 0.06).
  • A significant inverse association of caffeine intake with breast cancers was observed among postmenopausal women; for the highest quintile of intake compared to the lowest RR 0.88 (95% CI = 0.79-0.97, p for trend = 0.03).
  • We observed no substantial association between caffeinated and decaffeinated coffee and tea consumption and risk of breast cancer in the overall cohort.
  • However, our results suggested a weak inverse association between caffeine-containing beverages and risk of postmenopausal breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18183588.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA050385; United States / NCI NIH HHS / CA / CA050385-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Coffee; 0 / Tea; 3G6A5W338E / Caffeine
  • [Other-IDs] NLM/ NIHMS600465; NLM/ PMC4186696
  •  go-up   go-down


11. Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, Chan KW: A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1006-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
  • PURPOSE: To verify feasibility and monitor progression-free survival and overall survival in children with high-risk medulloblastoma and noncerebellar primitive neuroectodermal tumors (PNETs) treated in a Phase II study with preradiotherapy chemotherapy (CHT) followed by high-dose, hyperfractionated craniospinal radiotherapy (CSRT).
  • Treatment was initiated with five alternating monthly cycles of CHT (A [cisplatin, cyclophosphamide, etoposide, and vincristine], B [carboplatin and etoposide], A, B, and A) followed by hyperfractionated CSRT (40 Gy) with a boost to the primary tumor (72 Gy) given in twice-daily 1-Gy fractions.
  • No significant differences were detected in subset analysis related to response to CHT, site of primary tumor, postoperative residual disease, or M stage.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):279-85 [10030250.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Cancer J. 2004 Nov-Dec;10(6):386-90 [15701271.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):727-34 [15763649.001]
  • [Cites] Australas Radiol. 2005 Aug;49(4):298-303 [16026436.001]
  • [Cites] Acta Oncol. 2005;44(6):554-62 [16165914.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):711-6 [15927408.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1287-94 [11483340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Feb;8(2):219-26 [7085377.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2001-6 [6627214.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):649-53 [3258630.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):754-60 [2715805.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):297-300 [2173440.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2755-62 [8402500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):371-8 [7836091.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1377-83 [7751882.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2247-54 [7666082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1155-61 [8985038.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):798-804 [9264364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):15-24 [9300735.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • (PMID = 19356859.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA003888-44; United States / NCI NIH HHS / CA / U10 CA003888; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA003888-44
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS128135; NLM/ PMC2739055
  •  go-up   go-down


12. Stiller CA: International patterns of cancer incidence in adolescents. Cancer Treat Rev; 2007 Nov;33(7):631-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system tumours and thyroid carcinoma were most often registered in countries with higher standard of living.
  • [MeSH-major] Neoplasms / epidemiology. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Female. Global Health. Humans. Incidence. Male. Risk Factors. Sex Distribution

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329031.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Bajer-Czajkowska A, Nowacki P: [Primary diffuse meningeal melanomatosis. Case report]. Neurol Neurochir Pol; 2007 Jan-Feb;41(1):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma malignum constitutes only 0.1% of central nervous system neoplasms.
  • A case of the latter form of central nervous system melanoma is presented in a 44-year-old man, suffering from headaches, cerebrospinal fluid protein elevation, optic disc oedema, hydrocephalus, seizures, cranial nerves and multilevel spinal root damage.
  • [MeSH-major] Melanoma / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330185.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Terasaki M, Bouffet E, Katsuki H, Fukushima S, Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol; 2008 Jan;69(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
  • BACKGROUND: The aim of this study was to determine the response and toxicity of patients with recurrent or treatment-induced brain tumors to TMZ and oral VP-16.
  • METHODS: Eleven patients with recurrent or treatment-induced malignant CNS tumors, including treatment-induced PNET (in 1 patient), brainstem glioma (in 3 patients; 1 with treatment-induced, 2 with recurrence), recurrent anaplastic astrocytoma (in 3 patients), and recurrent glioblastoma (in 4 patients) were evaluated in a pilot study of TMZ and oral VP-16 chemotherapy.
  • The histologic subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control.
  • CONCLUSION: This limited pilot study confirms the innocuousness and the activity of the combination of TMZ and oral VP-16 in recurrent malignant brain tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054615.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


15. Cheng YC, Lirng JF, Chang FC, Guo WY, Teng MM, Chang CY, Wong TT, Ho DM: Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system. Acta Radiol; 2005 Feb;46(1):89-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroradiological findings in atypical teratoid/rhabdoid tumor of the central nervous system.
  • PURPOSE: To evaluate the computed tomography (CT) and magnetic resonance imaging (MRI) findings of atypical teratoid tumor/rhabdoid tumor (AT/RT) of the central nervous system (CNS).
  • MATERIAL AND METHODS: Twenty cases of CNS AT/RT have been found over the past 23 years in our hospital; these involving 11 boys and 9 girls whose mean age at diagnosis was 5.5 years.
  • However, AT/RT should still remain in the differential diagnosis of brain tumors in young children, especially those located in the cerebellar hemisphere and with eccentric cysts.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radiography. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiography. Teratoma / pathology. Teratoma / radiography
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841745.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


16. Freschi G, Taddei A, Bechi P, Faiella A, Gulisano M, Cillo C, Bucciarelli G, Boncinelli E: Expression of HOX homeobox genes in the adult human colonic mucosa (and colorectal cancer?). Int J Mol Med; 2005 Oct;16(4):581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HOX homeobox genes in the adult human colonic mucosa (and colorectal cancer?).
  • We studied the expression of several homeobox genes of the HOX family in the adult human intestinal mucosa.
  • They have been found to be expressed in many embryonic tissues and axial structures like the central nervous system, the spine and in selected adult cells.
  • The expression of 39 HOX genes belonging to HOX-A, B, C and D was studied by in situ hybridization on specimens of mucosa from normal adult colon.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Caco-2 Cells. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Gene Expression. Humans. In Situ Hybridization. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142390.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / RNA, Messenger
  •  go-up   go-down


17. Mussak E, Lin J, Prasad M: Cavernous hemangioma of the maxillary sinus with bone erosion. Ear Nose Throat J; 2007 Sep;86(9):565-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The substantial bone destruction and resultant widening of the right ostiomeatal complex made it difficult to differentiate this cavernous hemangioma from malignant epithelial tumors.
  • [MeSH-major] Bone Diseases / pathology. Hemangioma, Cavernous, Central Nervous System / complications. Maxillary Sinus / pathology. Maxillary Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970148.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bare JB, Abramowsky CR, Hayes LL, Shehata BM: Congenital immature teratoma of the central nervous system: three case reports with literature review. Fetal Pediatr Pathol; 2007 May-Jun;26(3):109-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital immature teratoma of the central nervous system: three case reports with literature review.
  • All tumors were deemed to be unresectable.
  • Congenital CNS teratoma should be considered in the differential diagnosis of fetuses diagnosed with macrocephaly or hydrocephaly.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Fetal Diseases / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Gestational Age. Humans. Male. Pregnancy. Prenatal Diagnosis. Review Literature as Topic

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886021.001).
  • [ISSN] 1551-3815
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kobayashi TK, Bamba M, Ueda M, Nishino T, Muramatsu M, Hino A, Shima A, Echigo T, Oka H: Cytologic diagnosis of central neurocytoma in intraoperative squash preparations: a report of 2 cases. Acta Cytol; 2010 Mar-Apr;54(2):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of central neurocytoma in intraoperative squash preparations: a report of 2 cases.
  • BACKGROUND: Central neurocytoma is a rare central nervous system tumor typically found in the lateral ventricles and at the spectrum pellucidum.
  • Two patients with central neurocytoma underwent intraoperative frozen section diagnoses, and the cytologic evaluations are described.
  • Magnetic resonance imaging (MRI) showed enhancement of a ventricular tumor.
  • Over 80% of the tumor was removed, but after 14 months' follow-up, the disease progressed and regrowth occurred.
  • The patient had a second tumor resection with gamma knife surgery.
  • An MRI showed an enhancement of a ventricular tumor, and complete tumor removal was achieved.
  • In both cases histopathologic examination was consistent with a central neurocytoma.
  • Immunohistochemistry of both tumors was synaptophysin(+), NSE (+), NeuN(+), GFAP(-), but MIB-1 labeling index was 3.4% in case 1 and 1.1% in case 2.
  • CONCLUSION: These are 2 illustrative cases in which the authors report cytologic evaluation of central neurocytomna in intraoperative preparations.
  • These tumors possess distinct cellular features that help with the intraoperative distinction from other intraventricular tumors.
  • Moreover, it should be emphasized that immunostains for neural markers are essential for distinguishing them from other clear cell tumors of the brain, especially oligodendroglioma and clear cell ependymomal neoplasm.
  • A combination of imaging, cytomorphology and immunohistochemical features of central neurocytoma can help to differentiate this condition from other intraventricular tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adult. Antigens, Nuclear / metabolism. Cytodiagnosis / methods. Female. Humans. Immunohistochemistry. Nerve Tissue Proteins / metabolism. Phosphopyruvate Hydratase / metabolism. Synaptophysin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391982.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nerve Tissue Proteins; 0 / Synaptophysin; 0 / neuronal nuclear antigen NeuN, human; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


20. Benedetti E, Galzio R, D'Angelo B, Cerù MP, Cimini A: PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. PPAR Res; 2010;2010:427401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.
  • Neuroepithelial tumors represent a heterogeneous class of human tumors including benignant and malignant tumors.
  • The incidence of central nervous system neoplasms ranges from 3.8 to 5.1 cases per 100,000 in the population.
  • Among malignant neuroepithelial tumors, with regard to PPAR ligands, the most extensively studied were tumors of astrocytic origin and neuroblastoma.
  • PPARs are expressed in developing and adult neuroepithelial cells, even if with different localization and relative abundance.
  • The majority of malignant neuroepithelial tumors have poor prognosis and do not respond to conventional therapeutic protocols, therefore, new therapeutic approaches are needed.
  • This review will focus on the major studies dealing with PPAR expression in gliomas and neuroblastoma and the therapeutic implications of using PPAR agonists for the treatment of these neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1129-38 [10706135.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):121-38 [10725467.001]
  • [Cites] Biochim Biophys Acta. 2000 May 1;1474(3):397-409 [10779693.001]
  • [Cites] J Neurosci Res. 2000 Jul 1;61(1):67-74 [10861801.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5119-28 [10866668.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):330-9 [10935488.001]
  • [Cites] J Neurosci. 2000 Sep 15;20(18):6862-7 [10995830.001]
  • [Cites] EXS. 2000;89:141-51 [10997287.001]
  • [Cites] Int J Dev Biol. 2000 Aug;44(5):429-42 [11032176.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5558-64 [11034103.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Neuropathology. 2000 Sep;20(3):161-9 [11132930.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):98-104 [11205925.001]
  • [Cites] Glia. 2001 Mar 1;33(3):191-204 [11241737.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):160-6 [11307058.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):37-41 [11464901.001]
  • [Cites] Neurochem Res. 2006 Nov;31(11):1305-16 [17053972.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1134-7 [17184491.001]
  • [Cites] Neurosci Lett. 2007 Apr 24;417(1):72-7 [17324516.001]
  • [Cites] J Cell Physiol. 2007 Jun;211(3):837-47 [17390299.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1745-54 [17541035.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1771(8):1031-45 [17569578.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):2093-106 [17662640.001]
  • [Cites] J Cell Physiol. 2008 Oct;217(1):93-102 [18446822.001]
  • [Cites] Stem Cell Rev. 2008 Dec;4(4):293-303 [18561036.001]
  • [Cites] Acta Pharmacol Sin. 2009 Jul;30(7):935-46 [19503102.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4195-202 [11564675.001]
  • [Cites] J Neurocytol. 2001 Jan;30(1):21-33 [11577243.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1747-55 [11698335.001]
  • [Cites] Bull Cancer. 2002 Jan;89(1):23-8 [11847022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2613-8 [11867749.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Int J Dev Biol. 2002 Jan;46(1):105-14 [11902671.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):1052-60 [12065618.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5114-27 [12077340.001]
  • [Cites] J Neurocytol. 2001 Aug;30(8):671-83 [12118155.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1141-50 [12370766.001]
  • [Cites] J Chem Neuroanat. 2003 Jan;25(1):29-38 [12573457.001]
  • [Cites] Curr Opin Lipidol. 2003 Apr;14(2):129-35 [12642780.001]
  • [Cites] Front Biosci. 2003 May 1;8:d577-88 [12700119.001]
  • [Cites] Brain Res. 2003 Jun 13;975(1-2):10-21 [12763589.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] J Neurochem. 2003 Nov;87(3):742-51 [14535956.001]
  • [Cites] Neuroscience. 2004;123(1):131-45 [14667448.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):8976-85 [14699130.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23882-91 [15051725.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):83-91 [15171682.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):419-29 [15231248.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):493-502 [15254749.001]
  • [Cites] Oncol Res. 2004;14(7-8):345-54 [15301425.001]
  • [Cites] Biochem Soc Trans. 2004 Nov;32(Pt 5):840-2 [15494029.001]
  • [Cites] Neuroscience. 2005;130(2):325-37 [15664689.001]
  • [Cites] J Pharmacol Exp Ther. 2005 May;313(2):806-13 [15665144.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14145-53 [15695504.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2340-5 [15701701.001]
  • [Cites] Neuroscience. 2005;131(3):577-87 [15730864.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18667-82 [15774422.001]
  • [Cites] Neoplasma. 2005;52(2):126-36 [15800711.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2684-94 [15829979.001]
  • [Cites] Toxicology. 2005 Sep 15;213(1-2):157-68 [16009482.001]
  • [Cites] Prog Lipid Res. 2006 Mar;45(2):120-59 [16476485.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] Apoptosis. 2006 Sep;11(9):1503-12 [16820965.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1524-33 [16887936.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Sep;15(9):1039-49 [16916271.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):879-88 [16969347.001]
  • [Cites] Cell. 1992 Mar 6;68(5):879-87 [1312391.001]
  • [Cites] J Cell Physiol. 1992 Sep;152(3):536-44 [1506412.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):645-50 [2129546.001]
  • [Cites] N Engl J Med. 1985 Oct 31;313(18):1111-6 [4047115.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2643-52 [4748425.001]
  • [Cites] Science. 1984 Jun 8;224(4653):1121-4 [6719137.001]
  • [Cites] J Natl Cancer Inst. 1982 Apr;68(4):589-96 [7040765.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):354-66 [8536636.001]
  • [Cites] Cell Growth Differ. 1996 Jun;7(6):775-85 [8780891.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41 [8990192.001]
  • [Cites] J Neurosci Res. 1998 Mar 1;51(5):563-73 [9512000.001]
  • [Cites] J Neurochem. 1998 Apr;70(4):1366-75 [9523552.001]
  • [Cites] Endocrinology. 1998 Jun;139(6):2748-54 [9607781.001]
  • [Cites] Mol Cell. 1998 Feb;1(3):465-70 [9660931.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3344-52 [9699665.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):137-43 [9744270.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1049-55 [9797355.001]
  • [Cites] J Nutr. 1999 Feb;129(2S Suppl):575S-580S [10064336.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35881-8 [10585473.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):103-8 [10638762.001]
  • [Cites] J Med Chem. 2000 Feb 24;43(4):527-50 [10691680.001]
  • (PMID = 20339586.001).
  • [ISSN] 1687-4765
  • [Journal-full-title] PPAR research
  • [ISO-abbreviation] PPAR Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2841252
  •  go-up   go-down


21. Takami A, Hayashi T, Kita D, Nishimura R, Asakura H, Nakao S: Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab. Cancer Sci; 2006 Jan;97(1):80-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
  • We describe an immunocompetent 19-year-old man with CD20-positive primary central nervous system (CNS) lymphoma refractory to chemotherapy and irradiation.
  • After intraventricular administration of rituximab, a chimeric anti-CD20 monoclonal antibody, supplemented with autologous serum, a remarkable response developed to the CNS parenchymal lymphoma.
  • Cytotoxicity assays showed that untreated patient's serum with rituximab, but not that of heat-inactivated patient's serum with rituximab or rituximab alone, induced potent rituximab-mediated cytotoxicity against tumor cells in the patient's cerebrospinal fluid, suggesting induction of complement-dependent cytotoxicity against CNS lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / immunology. Central Nervous System Neoplasms / therapy. Complement System Proteins / drug effects. Lymphoma / immunology. Lymphoma / therapy. Serum
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cell Line. Humans. Immunotherapy. Injections, Intraventricular. Male. Rituximab. Tomography Scanners, X-Ray Computed

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2006; 97: 80 -83).
  • (PMID = 16367925.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


22. Muñoz-Mármol AM, Mola G, Ruiz-Larroya T, Fernández-Vasalo A, Vela E, Mate JL, Ariza A: Rarity of JC virus DNA sequences and early proteins in human gliomas and medulloblastomas: the controversial role of JC virus in human neurooncogenesis. Neuropathol Appl Neurobiol; 2006 Apr;32(2):131-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, JCV genomic DNA and early viral protein T-antigen have been detected in various types of human central nervous system (CNS) neoplasms.
  • To further explore this association we have studied paraffin-embedded brain biopsy tissue from 60 neoplasms (55 gliomas and five medulloblastomas) and 15 reactive gliosis cases for the presence of JCV DNA sequences and proteins.
  • Five cases (three neoplasms and two reactive gliosis instances) showed low viral DNA levels when PCR-tested for VP3 or large T, while no case was immunoreactive for any of the two antibodies used.
  • Additionally, IHC with both antibodies was applied to a tissue micro-array including 109 CNS tumours and 21 reactive gliosis samples.
  • [MeSH-major] Brain Neoplasms / virology. DNA, Viral / isolation & purification. Glioma / virology. JC Virus / genetics. Medulloblastoma / virology
  • [MeSH-minor] Adult. Animals. Antigens, Viral, Tumor / isolation & purification. Cell Transformation, Neoplastic. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599942.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Viral
  •  go-up   go-down


23. Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM: A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol; 2008 Nov;90(2):229-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was tumor response, assessed by MRI.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Central Nervous System Neoplasms / drug therapy. Glioblastoma / drug therapy. Immunosuppressive Agents / therapeutic use. Thalidomide / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Aug 12;356(9229):566-7 [10950238.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4 Suppl 3):23-6 [12014864.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6621-8 [14528287.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1745-8 [14534892.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):365-75 [15015670.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):417-23 [9054955.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2044-6 [15470485.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):295-301 [15864130.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 25;821(2):221-8 [15936253.001]
  • [Cites] J Pharm Biomed Anal. 2005 Sep 1;39(1-2):299-304 [16085147.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1549-51 [16350272.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1568-74 [16342649.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16687729.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16696148.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):420-2 [16680743.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1883-90 [16986123.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Sep;4(9):658-9 [17099621.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2339-43 [17107907.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):216-22 [18314417.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):113-8 [18438609.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Oct;26(5):351-62 [11006136.001]
  • (PMID = 18661102.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023108
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS539769; NLM/ PMC3885231
  •  go-up   go-down


24. Iliopoulos O, Chan-Smutko G, Gonzalez RG, Louis DN, Stone JR: Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the left [corrected] hand and hypertension. N Engl J Med; 2006 Jul 27;355(4):394-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Central Nervous System / pathology. Pheochromocytoma / genetics. von Hippel-Lindau Disease / diagnosis
  • [MeSH-minor] Adrenal Gland Neoplasms. Adult. Central Nervous System Neoplasms / pathology. Diagnosis, Differential. Fatal Outcome. Hand. Humans. Hypertension / etiology. Hypesthesia / etiology. Magnetic Resonance Imaging. Male. Mutation. Paraganglioma / diagnosis. Pedigree

  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] N Engl J Med. 2006 Sep 14;355(11):1184
  • (PMID = 16870919.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Dou T, Wu Q, Chen X, Ribas J, Ni X, Tang C, Huang F, Zhou L, Lu D: A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population. J Cancer Res Clin Oncol; 2010 Dec;136(12):1853-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, a significant association was observed between this genotype and glioma risk in the subgroups of adult glioma (OR = 0.73, 95% CI:0.55-0.98), male glioma (OR = 0.69, 95% CI:0.48-0.99) and patients with glioblastoma (OR = 0.58, 95% CI:0.37-0.91).
  • This may be related to the diversity on the tissue origin, tumor type, tumorigenesis, and developing process.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glioma / genetics. MicroRNAs / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adolescent. Adult. Alleles. Asian Continental Ancestry Group / genetics. Case-Control Studies. Chi-Square Distribution. Child. China. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Male. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2009 Jan;30(1):79-84 [18634034.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3300-5 [17360642.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Curr Opin Genet Dev. 2005 Oct;15(5):563-8 [16099643.001]
  • [Cites] Leukemia. 2007 May;21(5):912-6 [17330104.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1906-13 [17389609.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1183-7 [19293314.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Nature. 2005 Dec 1;438(7068):671-4 [16319892.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6667-78 [18663355.001]
  • [Cites] Hum Mol Genet. 2007 May 1;16(9):1124-31 [17400653.001]
  • [Cites] Trends Genet. 2008 Sep;24(9):448-56 [18674843.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):505-16 [17549010.001]
  • [Cites] Nat Genet. 2005 May;37(5):495-500 [15806104.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] J Pathol. 2006 May;209(1):15-24 [16463268.001]
  • [Cites] Science. 2004 Apr 23;304(5670):594-6 [15105502.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2600-8 [18521189.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8 [17991681.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3566-72 [18483236.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):987-9 [18398042.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Nat Genet. 2007 May;39(5):673-7 [17401365.001]
  • (PMID = 20229273.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MIRN196 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


26. Fuller CD, Choi M, Forthuber B, Wang SJ, Rajagiriyil N, Salter BJ, Fuss M: Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol; 2007;2:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intensity-modulated radiation therapy (IMRT) affords unparalleled capacity to deliver conformal radiation doses to tumors in the central nervous system.
  • Thirty-three patients with primary disease and 9 patients with recurrent tumors were included.
  • Thirty-four patients (81%) had surgery, with gross tumor resection in 13 patients (36%); 22 patients (53%) received chemo-radiotherapy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Central Nervous System / radiation effects. Glioblastoma / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Dosim. 2001 Spring;26(1):17-27 [11417503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):892-7 [16458777.001]
  • [Cites] Int J Cancer. 2001 Dec 20;96(6):341-9 [11745504.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):606-11 [12478010.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):219-32 [12707711.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):271-7 [12913080.001]
  • [Cites] Cancer J. 2003 May-Jun;9(3):149-56 [12952300.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1745-8 [14534892.001]
  • [Cites] Med Dosim. 2003 Winter;28(4):261-5 [14684191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):247-52 [14697445.001]
  • [Cites] Radiother Oncol. 2004 Jun;71(3):339-45 [15172151.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):997-1007 [6349785.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Strahlenther Onkol. 1991 Jan;167(1):7-13 [1846983.001]
  • [Cites] Radiother Oncol. 1991 Feb;20(2):99-110 [1851573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(1-2):29-33 [8748864.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1141-9 [9539570.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):287-92 [10030251.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):157-61 [10328588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Strahlenther Onkol. 2001 Aug;177(8):424-31 [11544905.001]
  • (PMID = 17629934.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1939706
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


27. Iwai Y, Yamanaka K, Yoshimura M: Intracerebral cavernous malformation induced by radiosurgery. Case report. Neurol Med Chir (Tokyo); 2007 Apr;47(4):171-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nevertheless, MR imaging showed regrowth of the tumor 1 year later, so radiosurgery was repeated on the same lesion.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Central Nervous System Vascular Malformations / etiology. Lung Neoplasms / pathology. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457021.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer; 2005 Jun 15;103(12):2606-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
  • BACKGROUND: The treatment of malignant brain tumors is hampered by the presence of the blood-brain barrier, which limits chemotherapy penetration to the central nervous system (CNS).
  • The authors detail their experience so far with the procedure in the context of an open Phase II study in the treatment of malignant brain tumors.
  • METHODS: Patients with histologically proven malignant gliomas, primitive neuroectodermal tumors, primary CNS lymphomas, and metastatic disease to the brain were eligible.
  • The overall median survival times (MST) from treatment initiation for glioblastoma multiforme (GBM), anaplastic oligodendrogliomas, primary CNS lymphomas, and metastases were, respectively, 9.1, 13.9, not reached, and 9.9 months, whereas time to disease progression was 4.1, 9.2, 12.3, and 3.3 months.
  • CONCLUSIONS: These encouraging results prompted the authors to further refine their knowledge of the potential contribution of this procedure in the treatment of brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Carboplatin / therapeutic use. Infusions, Intra-Arterial. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Disease Progression. Drug Delivery Systems. Female. Glioblastoma / drug therapy. Glioblastoma / pathology. Humans. Lymphoma / drug therapy. Lymphoma / pathology. Male. Middle Aged. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / pathology. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15880378.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


29. Lenzi J, Seferi A, Nardone A, Salvati M, Vreto G, Santoro A, Raco A, Pichierri A, Petrela M: Sylvian subarachnoid and extra-pial cavernous angioma. J Neurosurg Sci; 2005 Dec;49(4):163-6; discussion 166
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cavernous angiomas are one of the four types of vascular malformations of the central nervous system.
  • [MeSH-major] Hemangioma, Cavernous / pathology. Subarachnoid Space / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Subarachnoid Hemorrhage / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Angioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374409.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Hassan NA, Gunaid AA, Murray-Lyon IM: Khat (Catha edulis): health aspects of khat chewing. East Mediterr Health J; 2007 May-Jun;13(3):706-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catha edulis Forsk leaves (khat) are chewed daily by a high proportion of the adult population in Yemen for the mild stimulant effect.
  • The objective of this literature review was to examine studies on khat, particularly human studies, with special reference to its effect on the central nervous system, cardiovascular, digestive and genitourinary systems, oral-dental tissues, diabetes mellitus and cancer.
  • [MeSH-minor] Adult. Alkaloids / adverse effects. Alkaloids / analysis. Cardiovascular System / drug effects. Central Nervous System / drug effects. Diabetes Complications / complications. Digestive System / drug effects. Female. Fetus / drug effects. Health Planning Guidelines. Health Services Needs and Demand. Humans. Infant Welfare. Infant, Newborn. Male. Mastication. Neoplasms / chemically induced. Neoplasms / epidemiology. Oral Health. Plant Leaves / adverse effects. Pregnancy. Reproductive Medicine. Urogenital System / drug effects. Yemen / epidemiology

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. Cathinone .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687845.001).
  • [ISSN] 1020-3397
  • [Journal-full-title] Eastern Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ
  • [ISO-abbreviation] East. Mediterr. Health J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Alkaloids; 540EI4406J / cathinone
  • [Number-of-references] 76
  •  go-up   go-down


31. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P, van den Berg A: Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol; 2009 Apr;22(4):547-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.
  • Apart from 19 nodal cases without extranodal dissemination (stages I and II), we selected two groups with unambiguous stages I and II extranodal presentation; 9 cases of primary central nervous system, 11 cases of primary testicular and 11 cases of other primary extranodal diffuse large B-cell lymphomas.
  • In situ hybridization for the most differentially expressed miRNAs was performed to show miRNA expression in tumor cells, but not in background cells.
  • MiR-17-5p showed a significant higher expression level in the central nervous system compared with testicular and nodal diffuse large B-cell lymphomas (P<0.05).
  • MiR-127 levels were significantly higher in testicular than in central nervous system and in nodal diffuse large B-cell lymphomas (P<0.05).
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. MicroRNAs / biosynthesis. Testicular Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Germinal Center / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287466.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN17 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


32. Manders K, van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA, Roumen RM, Voogd AC: Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer; 2006;6:179
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Before they died, 70% of the 116 patients developed metastases in one or more bones, 50% in the lung and/or pleura, 50% in the abdominal viscera, 23% in the central nervous system, and 19% in the skin.
  • Patients younger than 50 years were much more likely to develop metastases in the central nervous system than patients 50 years and older.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy
  • [MeSH-minor] Adult. Age Distribution. Aged. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998;77(2):336-40 [9461007.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):671-9 [8636786.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):67-78 [10517344.001]
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):312-8 [15979804.001]
  • [Cites] J Clin Epidemiol. 1999 Dec;52(12):1131-6 [10580775.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):81-7 [11249054.001]
  • [Cites] Breast Cancer Res Treat. 2001 Feb;65(3):233-40 [11336245.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2301-12 [11094303.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):197-207 [11885995.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1466-73 [12110492.001]
  • [Cites] Cancer. 2002 May 15;94(10):2698-705 [12173339.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):545-53 [12548595.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):207-10 [14760110.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2):234-48 [15112153.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):810-6 [15305414.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3302-8 [15310773.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Aug;16(5):345-9 [15341438.001]
  • [Cites] BMJ. 1989 Jan 7;298(6665):13-4 [2492839.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):449-55 [1558803.001]
  • [Cites] JAMA. 1992 Jul 1;268(1):57-62 [1608114.001]
  • [Cites] J Natl Cancer Inst. 1994 Dec 7;86(23):1766-70 [7966414.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1030-5 [9508187.001]
  • (PMID = 16824210.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1534056
  •  go-up   go-down


33. Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S: Non-Hodgkin lymphoma of the breast. Cancer; 2007 Jul 1;110(1):25-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary lymphoma of the breast has been reported to have a high local and central nervous system recurrence (CNS) rate, suggesting the need for consolidation radiotherapy and CNS prophylaxis.
  • Four (11%) patients presented with bilateral breast involvement, with only 1 patient presenting with CNS disease.
  • No recurrences occurred in the involved breast and a single parenchymal CNS recurrence was recorded.
  • A single CNS recurrence was observed in our series of patients, most of whom presented with limited disease.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / analysis. Central Nervous System / pathology. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17541937.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Ki-67 Antigen; 80168379AG / Doxorubicin
  •  go-up   go-down


34. AIRTUM Working Group: [Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients]. Epidemiol Prev; 2010 Sep-Dec;34(5-6 Suppl 2):1-188
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients aged 75 years or more, the proportions of prevalent cases were 19%in males and 13%in females, and 10%between 60 and 75 years of age in both genders.More than half a million Italian women were alive with a breast cancer diagnosis (42%of women with a neoplasm), followed by women with cancers of the colonrectum (12%), corpus uteri (7%), thyroid (5%), and cervix uteri (4%).
  • Percentages of long-term survivors higher than 70% were reported for cancers of the cervix uteri (82% at five years, and 55% at 15 years from diagnosis), Hodgkin lymphoma, testis, brain and central nervous system, bone and connective tissue.
  • [MeSH-major] Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Databases, Factual. Epidemiologic Studies. Female. Humans. Infant. Italy / epidemiology. Male. Middle Aged. Prevalence. Registries. Remission Induction. Survivors / statistics & numerical data. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220827.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Investigator] Guzzinati S; Dal Maso L; De Angelis R; De Paoli A; Buzzoni C; Crocetti E; Bucchi L; Casella C; Cuccaro F; Fusco M; Luminari S; Madeddu A; Mangone L; Patriarca S; Piffer S; Stracci F; Tagliabue G; Tumino R; Zappa M; Capocaccia R; Ferretti S; Mazzoleni G; Bellú F; Tschugguel B; De Valiere E; Facchinelli G; Falk M; Dal Cappello T; Giacomin A; Vercellino PC; Andreone S; Busato A; Marzola L; Migliari E; Carletti N; Nenci I; Caldarella A; Corbinelli A; Giusti F; Intrieri T; Manneschi G; Nemcova L; Romeo G; Sacchettini C; Paci E; Serraino D; Angelin T; Bidoli E; de Dottori M; De Santis E; Forgiarini O; Zucchetto A; Zanier L; Vercelli M; Orengo MA; Marani E; Puppo A; Celesia MV; Cogno R; Manenti S; Garrone E; Quaglia A; Pannozzo F; Busco S; Rashid I; Ramazzotti V; Cercato MC; Battisti W; Sperduti I; Macci L; Bugliarello E; Bernazza E; Tamburo L; Rossi M; Curatella S; De Francesco C; Tamburrino S; Bisanti L; Autelitano M; Randi G; Ghilardi S; Leone R; Filipazzi L; Bonini A; Giubelli C; Federico M; Artioli ME; Valla K; Braghiroli B; Cirilli C; Pirani M; Ferrari L; Bellatalla C; Fusco M; Panico M; Perrotta C; Vassante B; Traina A; Carruba G; Cusimano R; Amodio R; Dolcemascolo C; Staiti R; Zarcone M; Michiara M; Bozzani F; Sgargi P; Cilia S; La Rosa MG; Cascone G; Frasca G; Giurdanella MC; Martorana C; Morana G; Nicita C; Rollo P; Ruggeri MG; Sigona A; Spata E; Vacirca S; Di Felice E; Pezzarossi A; Caroli S; Pellegri C; Vicentini M; Storchi C; Cavuto S; Costa J; Falcini F; Colamartini A; Balducci C; Ravegnani M; Vitali B; Cordaro C; Caprara L; Giuliani O; Giorgetti S; Salvatore S; Palumbo M; Vattiato R; Ravaioli A; Foca F; Rinaldi E; Donato A; Iannelli A; Senatore G; Zevola A; Budroni M; Cesaraccio R; Pirino D; Carboni D; Fiori G; Soddu M; Mameli G; Mura F; Contrino ML; Tisano F; Sciacca S; Muni A; Mizzi M; Russo M; Tessandori R; Ardemagni G; Gianola L; Maspero S; Annulli ML; Moroni E; Roberto G; Zanetti R; Rosso S; Prandi R; Sobrato I; Gilardi F; Busso P; Franchini S; Gentilini MA; Battisti L; Cappelletti M; Moser M; La Rosa F; D'Alò D; Scheibel M; Costarelli D; Spano F; Rossini S; Santucci C; Petrinelli AM; Solimene C; Bianconi F; Brunori V; Crosignani P; Contiero P; Preto L; Tittarelli A; Maghini A; Codazzi T; Frassoldi E; Gada D; Costa E; di Grazia L; Zambon P; Baracco M; Bovo E; Dal Cin A; Fiore AR; Greco A; Monetti D; Rosano A; Stocco C; Tognazzo S; Donato F; Limina RM; Adorni A; Andreis P; Zani G; Piovani F; Salvi O; Puleio M; Vitarelli S; Antonini S; Candela G; Pappalardo G; Scuderi T; Lottero B; Ribaudo M; Ricci P; Guarda L; Gatti L; Bozzeda A; Dall'Acqua M; Pironi V; Sutera Sardo A; Mazzei A; Sirianni N; Lavecchia AM; Mancuso P; Usala M; Pala F; Sini GM; Pintori N; Canu L; Demurtas G; Doa N; Pisani P; Pastore G; Magnani C; Terracini B; Cena T; Alessi D; Baussano I; Merletti F; Maule M; Mosso ML; Nonnato M; Rasulo A; Richiardi L; Zuccolo L; Pivetta E; Dalmasso P; Macerata V; Ponz de Leon M; Domati F; Rossi G; Goldoni CA; Rossi F; De Gaetani C; Benatti P; Roncucci L; Di Gregorio C; Pedroni M; Pezzi A; Maffei S; Mariani F; Borsi E; Cocchioni M; Pascucci C; Gennaro V; Lazzarotto A; Benfatto L; Mazzucco G; Montanaro F
  •  go-up   go-down


35. Hamir AN, Picton R, Blythe LL, Heidel JR: Diagnostic exercise: astrocytoma with involvement of medulla oblongata, spinal cord, and spinal nerves in a raccoon (Procyon lotor). Vet Pathol; 2008 Nov;45(6):949-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplasms affecting the central and peripheral nervous systems of wild animals are extremely rare.
  • Described are clinical signs and pathologic and immunohistochemical findings in an adult female raccoon (Procyon lotor) with an astrocytoma that involved medulla, cervical spinal cord, and roots of the cervical spinal nerves.
  • This appears to be the only reported case of astrocytoma that involved multiple anatomic sites in the central nervous system of this raccoon.
  • [MeSH-major] Astrocytoma / veterinary. Central Nervous System Neoplasms / veterinary. Medulla Oblongata / pathology. Raccoons. Spinal Cord / pathology. Spinal Nerves / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984803.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol; 2010 Jan;96(2):219-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) in a phase 2, open-label, single-arm trial.
  • Archival tumor samples were assessed for EGFR, EGFRvIII, PTEN, pAKT and pS6.
  • Tumor markers failed to show an association with PFS except for increased pAKT expression which achieved borderline significance (P = 0.045).

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5603-9 [18955445.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):99-105 [19018475.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1527-32 [11245461.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1758-64 [11410517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7291-7 [12499272.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4340-6 [14555504.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7443-50 [14612544.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3895-7 [8752154.001]
  • [Cites] Mol Pharmacol. 1998 Nov;54(5):815-24 [9804616.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3581-7 [10446965.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):329-38 [15558802.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):101-12 [15657358.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Drug Resist Updat. 2005 Feb-Apr;8(1-2):15-26 [15939339.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):357-61 [16012795.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5294-304 [15998902.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Neoplasia. 2005 Oct;7(10):921-9 [16242075.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8 [16467100.001]
  • [Cites] Cancer Cell. 2006 May;9(5):341-9 [16697955.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9 [16626884.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Neurology. 2006 Jul 11;67(1):156-8 [16832099.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3651-6 [16877733.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7864-9 [16912159.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3731-7 [17575239.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7401-6 [18094423.001]
  • [Cites] PLoS Med. 2008 Jan 22;5(1):e8 [18215105.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):957-60 [18281526.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):235-43 [18320068.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1575-84 [18260157.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3993-4001 [18559622.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2280-7 [18723475.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):89-97 [18581057.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4659-65 [18824712.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):579-84 [19075262.001]
  • (PMID = 19562254.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00672243
  • [Grant] United States / NINDS NIH HHS / NS / NS20023; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / NS020023-268626; United States / NINDS NIH HHS / NS / NS020023-240020; United States / NINDS NIH HHS / NS / NS020023-220020; United States / NINDS NIH HHS / NS / NS020023-250020; United States / NINDS NIH HHS / NS / P50 NS020023-210020; United States / NINDS NIH HHS / NS / P50 NS020023-230020; United States / NCI NIH HHS / CA / CA11898; United States / NINDS NIH HHS / NS / P50 NS020023-240020; United States / NCI NIH HHS / CA / P20 CA096890; United States / NINDS NIH HHS / NS / P50 NS020023-268626; United States / NCI NIH HHS / CA / CA096890-019003; United States / NINDS NIH HHS / NS / P50 NS020023-220020; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / P50 NS020023-250020; United States / NCI NIH HHS / CA / P20 CA096890-019003; United States / NCI NIH HHS / CA / R37 CA011898; United States / NINDS NIH HHS / NS / NS020023-210020; United States / NINDS NIH HHS / NS / NS020023-230020; United States / NCI NIH HHS / CA / 1 P20 CA096890
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS180484; NLM/ PMC2844073
  •  go-up   go-down


37. Zhou M, Shen D, Head JE, Chew EY, Chévez-Barrios P, Green WR, Chan CC: Ocular clusterin expression in von Hippel-Lindau disease. Mol Vis; 2007;13:2129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This retrospective case series included nine eyes with retinal hemangioblastoma/hemangioma associated with VHL disease, one eye from a patient with a history of VHL disease and central nervous system hemangioblastomas but without ocular lesions, one surgically-excised optic nerve with optic nerve hemangioblastoma/hemangioma, and three normal control eyes.
  • RESULTS: All retinal hemangioblastoma were composed of typical VHL tumor cells admixed with small vascular channels as well as glial cells.
  • CONCLUSIONS: Clusterin shows possible important functions in tumor suppression by the VHL gene product (pVHL) and the potential to be a novel biomarker in retinal hemangioblastoma associated VHL disease.
  • [MeSH-minor] Adult. Female. Hemangioblastoma / etiology. Hemangioblastoma / metabolism. Hemangioblastoma / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neuroglia / metabolism. Optic Nerve Neoplasms / etiology. Optic Nerve Neoplasms / metabolism. Optic Nerve Neoplasms / pathology. Polymerase Chain Reaction. RNA, Messenger / metabolism. Retina / metabolism. Retinal Neoplasms / etiology. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Vessels / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Eye Care.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 2000 Mar;25(3):95-8 [10694874.001]
  • [Cites] Neoplasma. 2007;54(1):46-50 [17203891.001]
  • [Cites] Nat Med. 2001 Mar;7(3):338-43 [11231633.001]
  • [Cites] Surv Ophthalmol. 2001 Sep-Oct;46(2):117-42 [11578646.001]
  • [Cites] Curr Eye Res. 2001 Sep;23(3):157-65 [11803476.001]
  • [Cites] Oncogene. 2002 Jan 31;21(6):929-36 [11840338.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):237-46 [12086860.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Nov;34(11):1430-48 [12200037.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38214-9 [12882985.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7076-80 [14612498.001]
  • [Cites] World J Gastroenterol. 2004 May 15;10(10):1387-91 [15133840.001]
  • [Cites] Glia. 2004 Jul;47(1):35-45 [15139011.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Cancer. 1976 Nov;38(5):2042-56 [1033029.001]
  • [Cites] Am J Ophthalmol. 1980 Apr;89(4):540-5 [7369317.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):1-29 [2642584.001]
  • [Cites] Q J Med. 1990 Nov;77(283):1151-63 [2274658.001]
  • [Cites] Ophthalmology. 1992 Jan;99(1):140-5 [1741127.001]
  • [Cites] J Neurochem. 1993 Oct;61(4):1498-505 [8377000.001]
  • [Cites] Am J Med. 1994 Aug;97(2):158-68 [8059782.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Radiology. 1995 Mar;194(3):629-42 [7862955.001]
  • [Cites] Ophthalmic Genet. 1995 Sep;16(3):79-84 [8556282.001]
  • [Cites] J Med Genet. 1996 Feb;33(2):120-7 [8929948.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):74-83 [9062583.001]
  • [Cites] Am J Hum Genet. 1997 Apr;60(4):765-71 [9106522.001]
  • [Cites] Hum Pathol. 1997 May;28(5):540-3 [9158701.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):504-8 [9458097.001]
  • [Cites] J Invest Dermatol. 1999 Mar;112(3):290-6 [10084304.001]
  • [Cites] Arch Ophthalmol. 1999 Mar;117(3):371-8 [10088816.001]
  • [Cites] Arch Ophthalmol. 1999 May;117(5):625-30 [10326959.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1999 Jun;237(6):513-7 [10379614.001]
  • [Cites] Am J Ophthalmol. 1958 Oct;46(4):525-34 [13583072.001]
  • [Cites] Trans Am Ophthalmol Soc. 2004;102:75-9; discussion 79-81 [15747747.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5675-86 [15964822.001]
  • [Cites] Mol Vis. 2005;11:697-704 [16163267.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38 [16153592.001]
  • [Cites] Cell Death Differ. 2006 Jan;13(1):12-9 [16179938.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):574-84 [16436671.001]
  • [Cites] Postepy Hig Med Dosw (Online). 2006;60:45-51 [16474275.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 May;47(5):1982-90 [16639006.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9256-61 [16754848.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):147-56 [17070589.001]
  • [Cites] Mol Vis. 2000 Oct 27;6:184-91 [11054462.001]
  • (PMID = 18079682.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22; United States / Intramural NIH HHS / / Z99 EY999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Clusterin; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS36212; NLM/ PMC2173882
  •  go-up   go-down


38. Preusser M, Woehrer A, Koperek O, Rottenfusser A, Dieckmann K, Gatterbauer B, Roessler K, Slavc I, Jaeger U, Streubel B, Hainfellner JA, Chott A: Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology; 2010;42(6):547-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
  • AIMS: Pathological and clinical data in a large series of immunocompetent patients with primary lymphoma of the central nervous system (PCNSL) were analysed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA-Binding Proteins / genetics. Female. Forkhead Transcription Factors / genetics. Gene Expression Profiling. Gene Rearrangement. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Repressor Proteins / genetics. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20854073.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / FOXP1 protein, human; 0 / Forkhead Transcription Factors; 0 / Repressor Proteins
  •  go-up   go-down


39. Huang F, Alrefae M, Langleben A, Roberge D: Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):752-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: In reviewing our experience with PCI as part of a complex protocol for advanced breast cancer, we present descriptive data on late central nervous system outcomes in those receiving PCI.
  • [MeSH-major] Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Breast Neoplasms. Cranial Irradiation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Clinical Protocols. Cognition Disorders / etiology. Combined Modality Therapy / methods. Fatal Outcome. Female. Humans. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction


40. Koh ES, Nichol A, Millar BA, Ménard C, Pond G, Laperriere NJ: Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys; 2007 Dec 1;69(5):1521-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system.
  • PURPOSE: To assess the clinical outcomes and toxicity in patients receiving fractionated external beam radiotherapy (EBRT) for hemangioblastoma of the central nervous system, treated at two Canadian radiation oncology institutions.
  • METHODS AND MATERIALS: Between January 1980 and December 2004, the data of all patients receiving EBRT for central nervous system hemangioblastoma were retrospectively reviewed.
  • The patient, tumor, and treatment characteristics were collected and overall survival, disease-free survival, and EBRT-related toxicities assessed.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Hemangioblastoma / radiotherapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. British Columbia. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Ontario. Radiation Injuries / complications. Retrospective Studies. von Hippel-Lindau Disease / complications

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869023.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


41. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


42. Jalali R, Datta D: Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol; 2008 Mar;87(1):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Cancer Care Facilities. Child. Female. Humans. Incidence. India / epidemiology. Male. Middle Aged. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 1999 Jul;1(3):205-11 [11554389.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):12-26 [16443944.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Indian J Cancer. 2005 Jan-Mar;42(1):40-5 [15805691.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1108-24 [16570271.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):199-204 [15690139.001]
  • (PMID = 18004503.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


43. Gatzonis S, Stranjalis G, Siatouni A, Boviatsis E, Sakas DE: Neurological picture. Multiple spinal intramedullary cavernomas with vascular skin nevus or 'Cobb syndrome': a case report. J Neurol Neurosurg Psychiatry; 2010 May;81(5):500-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Hemangioma, Cavernous / pathology. Nevus / pathology. Skin Neoplasms / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. Brain / pathology. Central Nervous System Vascular Malformations / pathology. Female. Humans. Magnetic Resonance Imaging. Muscle Spasticity / etiology. Neurologic Examination. Spinal Cord / pathology. Syndrome

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurol Neurosurg Psychiatry. 2011 Aug;82(8):944. Strantzalis, G [corrected to Stranjalis, G]
  • (PMID = 20460590.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Neff F, Weirich G, Herzog P, Schlosser H, Kiebach C, Schlegel J: A 35-year-old woman with an intrasellar and suprasellar lesion. Brain Pathol; 2008 Jan;18(1):108-9, 144-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Growth Hormone-Secreting Pituitary Adenoma / pathology. Pituitary Gland / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology. Tuberculosis, Central Nervous System / pathology
  • [MeSH-minor] Acromegaly / etiology. Acromegaly / physiopathology. Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. DNA, Bacterial / analysis. DNA, Bacterial / genetics. Encephalitis / microbiology. Encephalitis / pathology. Encephalitis / physiopathology. Female. Growth Hormone / metabolism. Growth Hormone / secretion. Humans. Magnetic Resonance Imaging. Mycobacterium tuberculosis / genetics. Neurosurgical Procedures. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226104.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Bacterial; 9002-72-6 / Growth Hormone
  •  go-up   go-down


45. Lossignol DA, Obiols-Portis M, Body JJ: Successful use of ketamine for intractable cancer pain. Support Care Cancer; 2005 Mar;13(3):188-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The emergence of intractable pain may notably be due to the activation of N-methyl-D-aspartate (NMDA) receptors located in the central nervous system.
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasms / complications. Neoplasms / diagnosis. Pain Measurement. Patient Satisfaction. Severity of Illness Index

  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. KETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pharmacol. 1990 Oct 23;187(3):513-8 [1963598.001]
  • [Cites] Brain Res. 1992 Feb 28;573(2):321-3 [1387029.001]
  • [Cites] Pain. 1987 Jan;28(1):61-8 [3822495.001]
  • [Cites] Pain. 1994 Jan;56(1):51-7 [8159441.001]
  • [Cites] Pain. 1990 Jun;41(3):273-81 [1697056.001]
  • [Cites] N Engl J Med. 1985 Jul 11;313(2):84-95 [2582259.001]
  • [Cites] Support Care Cancer. 1999 Jan;7(1):47-50 [9926975.001]
  • [Cites] Acta Anaesthesiol Scand. 1997 Jan;41(1 Pt 2):112-5 [9061093.001]
  • [Cites] Anesth Analg. 1998 Jun;86(6):1250-6 [9620514.001]
  • [Cites] Support Care Cancer. 1993 Sep;1(5):256-8 [8156236.001]
  • [Cites] Pain. 1995 Apr;61(1):55-9 [7644249.001]
  • [Cites] Pain. 1989 Jan;36(1):37-41 [2919093.001]
  • [Cites] Pain. 1995 Oct;63(1):65-76 [8577492.001]
  • [Cites] Pain. 1989 May;37(2):203-9 [2748193.001]
  • [Cites] Anesthesiology. 1982 Feb;56(2):119-36 [6892475.001]
  • [Cites] Pain. 1995 Nov;63(2):163-72 [8628581.001]
  • [Cites] J Pain Symptom Manage. 1999 Apr;17(4):296-300 [10203883.001]
  • [Cites] Neurosci Lett. 1992 Jan 20;135(1):67-70 [1311824.001]
  • (PMID = 15480820.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 690G0D6V8H / Ketamine; 76I7G6D29C / Morphine
  •  go-up   go-down


46. Mehta MP: Neuro-oncology: gangliogliomas--what is the appropriate management strategy? Nat Rev Neurol; 2010 Apr;6(4):190-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Ganglioglioma / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Humans. Neurosurgical Procedures. Radiotherapy. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379203.001).
  • [ISSN] 1759-4766
  • [Journal-full-title] Nature reviews. Neurology
  • [ISO-abbreviation] Nat Rev Neurol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  •  go-up   go-down


47. Sibtain NA, Butt S, Connor SE: Imaging features of central nervous system haemangiopericytomas. Eur Radiol; 2007 Jul;17(7):1685-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging features of central nervous system haemangiopericytomas.
  • [MeSH-major] Cerebral Angiography. Hemangiopericytoma / diagnosis. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Brain / pathology. Diagnosis, Differential. Dura Mater / blood supply. Dura Mater / pathology. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Pericytes / pathology. Sensitivity and Specificity. Spinal Cord Compression / diagnosis. Spinal Cord Compression / surgery

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Neurol. 1984;23(4):274-7 [6489389.001]
  • [Cites] Am J Surg. 1992 May;163(5):490-3 [1575304.001]
  • [Cites] Neuroradiology. 1994 Aug;36(6):440-5 [7991087.001]
  • [Cites] Neurosurgery. 2002 Mar;50(3):654-7 [11841738.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):359-62 [9950509.001]
  • [Cites] Surg Neurol. 2003 Jan;59(1):47-53; discussion 53-4 [12633961.001]
  • [Cites] AJNR Am J Neuroradiol. 1981 Jan-Feb;2(1):69-74 [6784553.001]
  • [Cites] Neurology. 1961 Jun;11:497-502 [13773875.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1491-7 [15042684.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):575-86 [11534674.001]
  • [Cites] J Neurosurg. 1970 May;32(5):539-44 [5461885.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23(4):282-5 [9315052.001]
  • [Cites] Radiology. 1980 Sep;136(3):665-75 [7403545.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):514-22 [2797389.001]
  • [Cites] Neuroradiology. 2004 Mar;46(3):194-7 [14991259.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Aug;17(7):1365-71 [8871726.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Dec;125(4):823-32 [1211512.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):227-36 [3975803.001]
  • (PMID = 17131127.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Betlej M, Czepko R, Lopatka P, Danilewicz B, Uhl H: [Diagnosis and operative treatment cavernous angiomas of the central nervous system]. Przegl Lek; 2006;63(2):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and operative treatment cavernous angiomas of the central nervous system].
  • The aim of this study is to present the diagnostic methods of CA of the central nervous system (CNS), indications for surgery and assessment of its outcome.
  • CONCLUSIONS:. (1) direct surgical outcome in CA of the CNS is good and very good in the majority of cases;.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / diagnosis. Hemangioma, Cavernous, Central Nervous System / surgery
  • [MeSH-minor] Adult. Epilepsy / etiology. Epilepsy / prevention & control. Female. Humans. Male. Middle Aged. Neurosurgical Procedures. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967711.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


49. Offiah CE, Turnbull IW: The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol; 2006 May;61(5):393-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients.
  • The spectrum of pathology affecting the central nervous system (CNS) in patients suffering from acquired immunodeficiency syndrome (AIDS) is broad and comprises predominantly opportunistic infections and neoplasms.
  • Attention will be paid specifically to those CNS manifestations occurring in the adult HIV and AIDS population as infection in the paediatric HIV and AIDS group, although bearing some similarities, demonstrates some important differences.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Central Nervous System Infections / diagnosis
  • [MeSH-minor] AIDS Dementia Complex / diagnosis. AIDS Dementia Complex / radiography. Adult. Cytomegalovirus Infections / diagnosis. Cytomegalovirus Infections / radiography. Encephalitis / diagnosis. Encephalitis / radiography. HIV-1. Humans. Leukoencephalopathy, Progressive Multifocal / diagnosis. Leukoencephalopathy, Progressive Multifocal / radiography. Magnetic Resonance Imaging / methods. Meningitis, Cryptococcal / diagnosis. Meningitis, Cryptococcal / radiography. Neurosyphilis / diagnosis. Neurosyphilis / radiography. Tomography, X-Ray Computed / methods. Toxoplasmosis, Cerebral / diagnosis. Toxoplasmosis, Cerebral / radiography. Tuberculosis, Central Nervous System / diagnosis. Tuberculosis, Central Nervous System / radiography

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679111.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


50. Kochbati L, Bouaouina N, Hentati D, Nasr C, Besbes M, Benna F, Boussen H, Maalej M: [Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors]. Cancer Radiother; 2006 May;10(3):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors].
  • [Transliterated title] Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors.
  • PURPOSE: Extra-central nervous system (extra-CNS) metastases are relatively unknown failure patterns in medulloblastoma.
  • The aim of this study was to analyse epidemiological, clinical and aetiopathological aspects of these extra-CNS localisations.
  • PATIENTS AND METHODS: Extra-CNS metastases were retrospectively identified in patients treated in the department of radiation therapy at Salah-Azaïz institute (ISA) for medulloblastoma.
  • These metastases were diagnosed as extra-CNS for all secondary localisations not related to other tumour aetiology.
  • RESULTS: Among 103 patients treated and followed-up in the department of radiation therapy of ISA from 1970 to 1992, 8 developed extra-CNS metastases (7.7%).
  • The mean free-interval from diagnosis of primitive tumour to extra-CNS metastases was 23 months, varying from 8 to 53 months.
  • All patients died or are in progressive disease in less than one year from the diagnosis of extra-CNS metastases.
  • CONCLUSION: Extra-CNS metastases are not rare and have a poor prognosis.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / secondary. Nervous System Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600659.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


51. Maranzano E, Trippa F, Pacchiarini D, Chirico L, Basagni ML, Rossi R, Bellavita R, Schiavone C, Italiani M, Muti M: Re-irradiation of brain metastases and metastatic spinal cord compression: clinical practice suggestions. Tumori; 2005 Jul-Aug;91(4):325-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • So, the number of cases with brain metastases and metastatic spinal cord compression has increased, as has the possibility of developing a recurrence in areas of the central nervous system already treated with radiotherapy.
  • The absence of extracranial disease was the most significant factor in conditioning survival, and maximum tumor diameter was the only variable associated with an increased risk of unacceptable acute and/or chronic neurotoxicity.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cranial Irradiation / methods. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Bone Marrow / radiation effects. Dose Fractionation. Female. Humans. Incidence. Male. Middle Aged. Necrosis / etiology. Practice Guidelines as Topic. Radiation Injuries / etiology. Radiosurgery. Radiotherapy / adverse effects. Retreatment. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277098.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L: EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol; 2009 Apr;20(4):648-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In an attempt to identify markers of resistance to trastuzumab, we evaluated both the profiling of human epidermal growth factor receptor 2 (HER2)-positive tumor cells measuring the relative levels of EGFR, pMAPK, pAkt and PTEN and their correlations with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
  • PATIENTS AND METHODS: Tumor tissues for this retrospective analysis were available from 45 out of 76 patients with metastatic breast cancer treated from April 1999 to March 2006 with trastuzumab-based therapy at our Institution.
  • Evaluations of EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry (IHC) were carried out on all 45 tissue samples and their correlations with response to trastuzumab, incidence of central nervous system (CNS) metastases, time to progression (TTP), overall survival from diagnosis of breast cancer (OS1), from diagnosis of metastatic disease (OS2) and from the start of trastuzumab (OS3) were analyzed.
  • EGFR, pMAPK, pAkt and PTEN status by IHC were not significantly associated with response to trastuzumab, TTP, overall survival (OS1, OS2, OS3) and CNS metastases incidence.
  • It is likely that high expression of pMAPK (pMAPK-positive status) or pAkt (pAkt-positive status) could identify a subgroup of HER2-positive tumors with high activity of proliferation and survival pathways and with resistance to trastuzumab.
  • CONCLUSIONS: In HER2-positive metastatic breast cancers, EGFR, pMAPK, pAkt and PTEN status evaluated by IHC was not significantly associated with response to trastuzumab, TTP, OS and CNS metastases incidence.


53. Järvelä S, Nordfors K, Jansson M, Haapasalo J, Helén P, Paljärvi L, Kalimo H, Kinnula V, Soini Y, Haapasalo H: Decreased expression of antioxidant enzymes is associated with aggressive features in ependymomas. J Neurooncol; 2008 Dec;90(3):283-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to investigate the relationship between antioxidant enzyme expression and clinicopathological features in 67 ependymal tumors.
  • Their expression was studied in 46 primary (10 grade I, 30 grade II and 6 grade III) and 21 recurrent (3 grade I, 12 grade II and 6 grade III) tumors.
  • Immunoreactivity for MnSOD was found in 87%, GLCL-C in 74%, GLCL-R in 89%, Trx in 72%, TrxR in 54%, of primary tumors.
  • Lower GLCL-C and GLCL-R expression was associated with higher tumor grade (P = 0.047 and 0.049, respectively).
  • MnSOD, GLCL-C and TrxR expressions were significantly higher in tumors located in the spinal cord compared to those in the brain (P = 0.044, 0.046 and 0.004, respectively).
  • In the primary tumors Trx-positivity was found to correlate significantly with patient survival.
  • In univariate survival analysis patients whose tumors did not express Trx had shorter survival (P = 0.045) and there was even more significant association (P = 0.011) when only adults were included in the analysis (in the total material median follow-up time of Trx-positive tumors was 9.7 years and of Trx-negative 5.4 years).
  • The results indicate that AOEs have several biological functions in ependymal tumors.
  • Trx had important prognostic value: all adults with Trx-positive tumors were alive at follow-up (median 7.8 years).
  • [MeSH-major] Antioxidants / metabolism. Central Nervous System Neoplasms / metabolism. Ependymoma / metabolism. Oxidoreductases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Superoxide Dismutase. Survival Analysis. Thioredoxin-Disulfide Reductase. Thioredoxins. Young Adult

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8670-3 [14695179.001]
  • [Cites] FEBS Lett. 2004 Jul 2;569(1-3):1-6 [15225599.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2001;30:421-55 [11441809.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24522-30 [10455115.001]
  • [Cites] J Pathol. 2002 Jun;197(2):238-44 [12015749.001]
  • [Cites] Free Radic Biol Med. 1996;21(4):527-32 [8886804.001]
  • [Cites] Genomics. 1992 Nov;14(3):823-5 [1427917.001]
  • [Cites] Chem Biol Interact. 1998 Apr 24;111-112:23-34 [9679540.001]
  • [Cites] Am J Med. 1991 Sep 30;91(3C):14S-22S [1928205.001]
  • [Cites] Histol Histopathol. 2006 Feb;21(2):157-65 [16329040.001]
  • [Cites] Mol Hum Reprod. 1998 Apr;4(4):369-75 [9620837.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4313-20 [8044778.001]
  • [Cites] Oncol Res. 1994;6(10-11):539-44 [7620223.001]
  • [Cites] Dev Biol. 1996 Aug 25;178(1):179-85 [8812119.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Free Radic Biol Med. 1992;13(1):47-53 [1628853.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1750-7 [11410516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6264-8 [7603981.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):324-9 [11118286.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):916-22 [12529397.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):1-21; discussion 21-2 [7708144.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):155-64 [12744469.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2596-606 [9564042.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):37-43 [10962437.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Biochem J. 2000 Feb 15;346 Pt 1:1-8 [10657232.001]
  • [Cites] Brain Res. 1994 Aug 1;652(2):304-10 [7953744.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):748-55 [12196927.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):376-81 [7493016.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 1):L530-9 [10070119.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1022-9 [10737384.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):871-82 [9499449.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3418-24 [12960131.001]
  • [Cites] Free Radic Biol Med. 2004 Mar 15;36(6):718-44 [14990352.001]
  • [Cites] Methods Enzymol. 1995;252:199-208 [7476354.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Apr;18(4):570-80 [9533946.001]
  • (PMID = 18682894.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 52500-60-4 / Thioredoxins; EC 1.- / Oxidoreductases; EC 1.15.1.1 / Superoxide Dismutase; EC 1.8.1.9 / Thioredoxin-Disulfide Reductase
  •  go-up   go-down


54. Cartwright G, Bailey BM, Lane RJ, Messiha A: A diagnostic dilemma of intracranial pathology: coincidence or the result of cranial trauma? BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Epilepsy, Tonic-Clonic / complications. Epilepsy, Tonic-Clonic / diagnosis. Facial Injuries / complications. Facial Injuries / diagnosis. Hemangioma, Cavernous, Central Nervous System / complications. Hemangioma, Cavernous, Central Nervous System / diagnosis. Intracranial Hemorrhage, Traumatic / complications. Intracranial Hemorrhage, Traumatic / diagnosis. Intracranial Hemorrhages / complications. Intracranial Hemorrhages / diagnosis. Muscle Weakness / complications. Muscle Weakness / diagnosis
  • [MeSH-minor] Brain / pathology. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Motor Cortex / pathology. Neurologic Examination. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Facial Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Scand. 2004 Dec;110(6):393-7 [15527452.001]
  • [Cites] Epilepsia. 2006 Mar;47(3):563-6 [16529622.001]
  • [Cites] Neurologist. 2008 Jan;14(1):46-9 [18195658.001]
  • [Cites] Neurol Neurochir Pol. 1999 May-Jun;33(3):603-12 [10540722.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Jul;54(7):590-4 [1895122.001]
  • [Cites] Neurosurg Rev. 1992;15(2):125-33 [1635626.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 May;66(5):561-8 [10209164.001]
  • (PMID = 22797209.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027484
  •  go-up   go-down


55. Labauge P, Fontaine B, Neau JP, Bergametti F, Riant F, Blecon A, Marchelli F, Arnoult M, Lannuzel A, Clanet M, Olschwang S, Denier C, Tournier-Lasserve E: Multiple dural lesions mimicking meningiomas in patients with CCM3/PDCD10 mutations. Neurology; 2009 Jun 9;72(23):2044-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Brain / pathology. Dura Mater / pathology. Hemangioma, Cavernous, Central Nervous System / genetics. Hemangioma, Cavernous, Central Nervous System / pathology. Membrane Proteins / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Cohort Studies. DNA Mutational Analysis. Female. Genetic Markers / genetics. Genetic Predisposition to Disease / genetics. Genetic Testing. Genotype. Humans. Male. Meningeal Neoplasms / pathology. Meningioma / pathology. Middle Aged. RNA Splice Sites / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506228.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Genetic Markers; 0 / Membrane Proteins; 0 / PDCD10 protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA Splice Sites
  •  go-up   go-down


56. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One; 2009;4(11):e7826
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.
  • BACKGROUND: Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia.
  • The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3 and M2 patients, respectively.
  • Importantly, we identified a "miRNA cascade" associated with central nervous system (CNS) relapse in ALL.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Leukemia / diagnosis. Leukemia / pathology. MicroRNAs

  • MedlinePlus Health Information. consumer health - Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] J Pediatr (Rio J). 2003 Mar-Apr;79(2):149-58 [14502336.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):167-73 [16616063.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2825-32 [18089852.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Dev Biol. 1999 Dec 15;216(2):671-80 [10642801.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):179-81 [12525506.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • (PMID = 19915715.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2773830
  •  go-up   go-down


57. Batoroev IuK: [Cytomorphological diagnosis in the primary central nervous system lymphoma]. Klin Lab Diagn; 2010 Jan;(1):32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytomorphological diagnosis in the primary central nervous system lymphoma].
  • The paper provides a retrospective analysis of cases of the cytological diagnosis of the rare abnormality--primary central nervous system (CNS) lymphomas.
  • The capabilities, advantages, and disadvantages of diagnosis of both cytological and histological diagnosis of CNS lymphomas are estimated.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphoma / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult


58. Sancho JM, Morgades M, Arranz R, Fernández-Abellán P, Deben G, Alonso N, Blanes M, Rodríguez MJ, Nicolás C, Sánchez E, Fernández de Sevilla A, Conde E, Ribera JM, QUIT Study (PETHEMA, GELTAMO and GOTEL Groups): Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. Med Clin (Barc); 2008 Oct 4;131(11):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
  • BACKGROUND AND OBJECTIVE: Central nervous system (CNS) involvement in patients diagnosed with acute leukemias (AL) is an uncommon complication with poor prognosis.
  • The indication and the schedules of prophylaxis and treatment of CNS involvement in AL are not homogenous among countries and within the same country.
  • The aim of this prospective longitudinal study was to analyze and report the practice of CNS prophylaxis and treatment in patients with AL in Spain.
  • Adult patients (> or = 18 yr.) diagnosed with AL who received CNS prophylaxis or treatment were consecutively included through online registration.
  • For acute lymphoblastic leukemia patients (n = 158), CNS therapy was given to 12 cases (10 at diagnosis and 2 at relapse) and consisted of triple intrathecal therapy (TIT, methotrexate, cytarabine and hydrocortisone) in 11 and liposomal depot cytarabine in one.
  • CNS prophylaxis (n = 146) consisted of TIT in 135 cases, intrathecal methotrexate in 7, intrathecal cytarabine in 2 and intrathecal liposomal depot cytarabine in 2.
  • In acute myeloblastic leukemia patients (n = 107), CNS therapy was administered to 17 cases (9 at diagnosis and 8 at relapse).
  • CNS prophylaxis (n = 90) consisted of TIT in 68 cases and intrathecal methotrexate in 22.
  • CONCLUSIONS: In Spain, the patterns of CNS prophylaxis and therapy for AL are homogeneous.
  • TIT was the most frequent schedule for CNS prophylaxis and therapy.
  • The lack of use of cranial or craniospinal irradiation and the administration of new drugs (i.e.: liposomal depot cytarabine) for CNS therapy and prophylaxis is of note.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Registries
  • [MeSH-minor] Adolescent. Adult. Anti-Inflammatory Agents / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Drug Therapy, Combination. Female. Humans. Hydrocortisone / administration & dosage. Injections, Spinal. Liposomes. Longitudinal Studies. Male. Methotrexate / administration & dosage. Middle Aged. Prospective Studies. Spain

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928719.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


59. Gasperini J, Black E, Van Stavern G: Perineural metastasis of breast cancer treated with optic nerve sheath fenestration. Ophthal Plast Reconstr Surg; 2007 Jul-Aug;23(4):331-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 36-year-old woman with bilateral optic neuropathy and orbital and central nervous system metastasis from breast carcinoma developed progressive bilateral vision loss with severe optic disc swelling.
  • [MeSH-major] Breast Neoplasms / pathology. Decompression, Surgical. Nerve Sheath Neoplasms / surgery. Optic Nerve / surgery. Optic Nerve Neoplasms / surgery. Orbital Neoplasms / surgery. Papilledema / surgery
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Myelin Sheath. Vision Disorders / diagnosis. Visual Fields

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667117.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Darmoul M, Habib Bouhaouala M, Smida H, Hedi Dougui M: [Pseudo-tumoral neuro-Behçet's disease]. Rev Neurol (Paris); 2006 May;162(5):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Clinical involvement of the central nervous system occurs in about 10 to 30 percent of patients with Behçet's disease.
  • CONCLUSION: The clinical and radiological presentation of neuro-Behçet's disease can mimic a brain tumor.
  • [MeSH-minor] Administration, Oral. Adult. Anti-Inflammatory Agents / administration & dosage. Aphasia / etiology. Brain Neoplasms / diagnosis. Consciousness Disorders / diagnosis. Cyclophosphamide / administration & dosage. Dominance, Cerebral / physiology. Drug Therapy, Combination. Headache / etiology. Hemiplegia / etiology. Humans. Immunosuppressive Agents / administration & dosage. Internal Capsule / pathology. Magnetic Resonance Imaging. Male. Mesencephalon / pathology. Methylprednisolone / administration & dosage. Thalamus / pathology

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710132.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


61. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, Thiel E, German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG): High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol; 2005 Mar;16(3):445-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
  • We evaluated HDMTX-related toxicity with special regard to age distribution in patients with primary central nervous system lymphoma (PCNSL) in a phase IV multicenter trial.

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653703.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


62. Zhao J, Wang Y, Kang S, Wang S, Wang J, Wang R, Zhao Y: The benefit of neuronavigation for the treatment of patients with intracerebral cavernous malformations. Neurosurg Rev; 2007 Oct;30(4):313-8; discussion 319
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data were transferred to the neuronavigation workstation, a profile of tumors was drawn up, and a three-dimensional reconstruction was completed.
  • [MeSH-major] Brain Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Neuronavigation
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2001 Dec;15(6):485-95 [11814000.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Jun;45(2):87-90 [12087505.001]
  • [Cites] Neurosurg Rev. 2002 Mar;25(1-2):1-53; discussion 54-5 [11954761.001]
  • [Cites] Acta Neurochir (Wien). 1990;105(1-2):14-23 [2239374.001]
  • [Cites] Chin Med J (Engl). 2004 Mar;117(3):323-6 [15043766.001]
  • [Cites] Eur J Ultrasound. 2000 Dec;12 (2):115-21 [11118918.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Sep;45(3):151-3 [12353162.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):351-5 [11861694.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):32-9 [2045915.001]
  • [Cites] Neurosurgery. 2003 Dec;53(6):1299-304; discussion 1304-5 [14633296.001]
  • [Cites] J Neurosurg. 1991 Nov;75(5):709-14 [1919692.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Apr;46(2):72-7 [12761675.001]
  • [Cites] Neurosurg Rev. 2003 Jan;26(1):53-61 [12520318.001]
  • (PMID = 17629759.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Chow EJ, Kamineni A, Daling JR, Fraser A, Wiggins CL, Mineau GP, Hamre MR, Severson RK, Drews-Botsch C, Mueller BA: Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med; 2009 Oct;163(10):887-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, preeclampsia was associated with some cancers, especially central nervous system tumors (relative risk, 3.36 [95% confidence interval, 1.63-6.90]).

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1997 Mar;176(3):521-6 [9077599.001]
  • [Cites] Arch Pediatr Adolesc Med. 2009 Oct;163(10):879-86 [19805705.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):53-9 [10401498.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):60-3 [10401499.001]
  • [Cites] BJOG. 2005 Feb;112(2):153-9 [15663578.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(34):72-6 [15784829.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(34):77-82 [15784830.001]
  • [Cites] Natl Vital Stat Rep. 2005 Jun 14;53(20):1-17 [15974501.001]
  • [Cites] Obstet Gynecol. 2002 Jan;99(1):159-67 [16175681.001]
  • [Cites] BMJ. 2005 Oct 15;331(7521):877 [16169871.001]
  • [Cites] N Engl J Med. 2001 Mar 22;344(12):867-72 [11259719.001]
  • [Cites] J Epidemiol Community Health. 2001 Dec;55(12):873-7 [11707480.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):1069-71 [11885031.001]
  • [Cites] Matern Child Health J. 2002 Sep;6(3):169-79 [12236664.001]
  • [Cites] Br J Cancer. 2003 Feb 10;88(3):382-7 [12569380.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):716-21 [12586811.001]
  • [Cites] Am J Epidemiol. 2003 May 15;157(10):940-3 [12746247.001]
  • [Cites] Natl Vital Stat Rep. 2003 Aug 4;51(12):1-94 [12918931.001]
  • [Cites] Med Care. 2003 Sep;41(9):1003-5 [12972839.001]
  • [Cites] Pediatr Blood Cancer. 2004 Apr;42(4):364-72 [14966835.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):91-103 [15313582.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):975-8 [2732008.001]
  • [Cites] Lancet. 1991 Oct 5;338(8771):869-71 [1681226.001]
  • [Cites] Med Pediatr Oncol. 1991;19(6):459-66 [1961132.001]
  • [Cites] Obstet Gynecol. 1996 Feb;87(2):163-8 [8559516.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):759-65 [8980180.001]
  • [Cites] Paediatr Perinat Epidemiol. 2005 Nov;19(6):460-71 [16269074.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1425-30 [16544312.001]
  • [Cites] Horm Res. 2006;65 Suppl 3:50-8 [16612114.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):1-11 [16718655.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1439-41 [17426701.001]
  • [Cites] Nature. 2007 May 24;447(7143):433-40 [17522677.001]
  • [Cites] Hum Reprod. 2008 Jan;23(1):178-86 [18024486.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 6;100(15):1048-9 [18664648.001]
  • [Cites] N Engl J Med. 1998 May 7;338(19):1339-44 [9571253.001]
  • (PMID = 19805706.001).
  • [ISSN] 1538-3628
  • [Journal-full-title] Archives of pediatrics & adolescent medicine
  • [ISO-abbreviation] Arch Pediatr Adolesc Med
  • [Language] ENG
  • [Grant] None / None / / N01 CN067000-003; United States / NCI NIH HHS / CN / N01 CN067000-003; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / CA / N01PC35141; United States / NCI NIH HHS / CN / N01 CN065064; United States / NCI NIH HHS / PC / PC005016-20; United States / NCI NIH HHS / PC / N01 PC067006-009; United States / NCI NIH HHS / PC / N01-PC-67006; United States / NCI NIH HHS / PC / N01 PC035141; United States / NCI NIH HHS / CN / N01-CN-05230; United States / NCI NIH HHS / PC / PC067006-009; United States / NCI NIH HHS / CN / N01 CN067000; United States / NCI NIH HHS / PC / N01 PC067006; United States / NCI NIH HHS / PC / N01-PC-05016-20; United States / NCI NIH HHS / PC / N01 PC005016-20; United States / NCI NIH HHS / PC / N01 PC005016; United States / NCI NIH HHS / CN / N01 CN005230; United States / NCI NIH HHS / CN / N01-CN-67000; United States / NCI NIH HHS / CN / N01-CN-65064
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS92714; NLM/ PMC2758644
  •  go-up   go-down


64. Kastritis E, Efstathiou E, Gika D, Bozas G, Koutsoukou V, Papadimitriou C, Pissakas G, Dimopoulos MA, Bamias A: Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer; 2006 May-Jun;16(3):994-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk factors and the prognostic significance of isolated central nervous system (CNS) relapse in patients with EOC who received primary treatment with platinum and paclitaxel have not been identified.
  • Patient and disease characteristics did not differ among patients who relapsed with isolated brain metastases and those with relapse outside the CNS.
  • Median time to first disease relapse, overall survival, and survival after relapse did not differ significantly between patients with brain metastases and those with relapse outside the CNS.
  • Three patients remain free of disease 4-18 months after treatment with radiotherapy and systemic chemotherapy for their CNS metastatic disease.
  • Patients with isolated brain metastases have comparable survival to patients with relapse outside the CNS, and long-term remission can be achieved in some cases, provided that systemic chemotherapy is added to local treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Echoencephalography. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / secondary. Recurrence. Retrospective Studies


65. Wang Z, Huang G, Yan P, Liang R, Wang J, Yan Q, Zhang J, Cheng H, Hu P, Ma MJ: Ectopic cervical anaplastic ependymoma. Pathol Int; 2005 Dec;55(12):781-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas generally arise in the central nervous system (CNS), although rare primary extraneural ependymomas have been observed.
  • The tumor was found in the right neck root region of a 35-year-old man.
  • No additional tumor was found in the CNS or in other parts of the body.
  • Microscopically, the tumor consisted of round to oval cells with fine chromatin, distinct nucleoli, moderate nuclear atypia and numerous mitoses (>25/10 high-power fields) in a densely cellular growth pattern with characteristic fibrillary cytoplasm and formation of perivascular pseudorosettes.
  • By immunohistochemistry, the tumor cells were positive for glial fibrillary acidic protein, epithelial membrane antigen (EMA), vimentin and S-100 protein.
  • Electron microscopic studies revealed that tumor cells form micro rosettes, into which microvilli and cilia projected.
  • There is no evidence of local tumor recurrence or distant metastasis after 30 months follow up.
  • The present case adds yet another unique example to the already diverse spectrum of head and neck neoplasms encountered in surgical pathology.
  • [MeSH-major] Ependymoma / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adult. Glial Fibrillary Acidic Protein / analysis. Humans. Male. Mucin-1 / analysis. Vimentin / analysis


66. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


67. Boban A, Radman I, Zadro R, Dubravcic K, Maretic T, Civljak R, Lisic M, Begovac J: Acute promyelocytic leukemia after whole brain irradiation of primary brain lymphoma in an HIV-infected patient. Eur J Med Res; 2009 Jan 28;14(1):42-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2004, the patient was diagnosed with primary central nervous system lymphoma.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. HIV Infections / complications. Leukemia, Promyelocytic, Acute / etiology. Leukemia, Radiation-Induced / etiology. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active / methods. Bisexuality. Humans. Idarubicin / therapeutic use. Male. Remission Induction. Tretinoin


68. Fuller CE, Perry A: Molecular diagnostics in central nervous system tumors. Adv Anat Pathol; 2005 Jul;12(4):180-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics in central nervous system tumors.
  • Central nervous system (CNS) neoplasms can be diagnostically challenging, due to remarkably wide ranges in histologic appearance, biologic behavior, and therapeutic approach.
  • In this regard, the field is primed by recent advances in basic research, elucidating the molecular mechanisms of tumorigenesis and progression in the most common adult and pediatric brain tumors.
  • Thus far, few have made the transition into routine clinical practice, the most notable example being 1p and 19q testing in oligodendroglial tumors.
  • The goal of this article is to highlight the most common genetic alterations currently implicated in CNS tumors, focusing most on those that are either already in common use in ancillary molecular diagnostics testing or are likely to become so in the near future.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / genetics. Polymerase Chain Reaction. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096380.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 260
  •  go-up   go-down


69. Seiz M, Nölte I, Pechlivanis I, Freyschlag CF, Schmieder K, Vajkoczy P, Tuettenberg J: Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. Neurosurg Rev; 2010 Jul;33(3):375-81; discussion 381
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / pathology. Central Nervous System Neoplasms / secondary. Cerebrospinal Fluid. Dacarbazine / analogs & derivatives. Glioblastoma / pathology. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Celecoxib. Combined Modality Therapy. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minim Invasive Neurosurg. 2001 Sep;44(3):175-7 [11696889.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):1011-2 [10526085.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804 [16585512.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):337-76 [12663862.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1159-66 [7653994.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Neoplasia. 2008 Dec;10 (12 ):1383-92 [19048117.001]
  • [Cites] Cancer. 1978 Dec;42(6):2854-64 [215298.001]
  • [Cites] Br J Neurosurg. 2008 Jun;22(3):452-5 [18568742.001]
  • [Cites] Can J Surg. 1959 Jul;2(4):363-5 [13662922.001]
  • [Cites] J Neurosurg. 1983 Feb;58(2):159-69 [6294260.001]
  • [Cites] J Neurosurg. 2005 Mar;102(3):540-2 [15796392.001]
  • [Cites] J Neurosurg. 1961 May;18:313-30 [13761772.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):64-71 [1738457.001]
  • [Cites] Pediatr Neurosurg. 1999 Nov;31(5):242-5 [10681678.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40 [15565458.001]
  • [Cites] Strahlenther Onkol. 2004 Jul;180(7):455-7 [15241534.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4934-40 [16000592.001]
  • [Cites] Curr Pharm Des. 2006;12(3):341-9 [16454748.001]
  • [Cites] Neurosurg Rev. 2000 Mar;23(1):39-44 [10809486.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] Br J Neurosurg. 2005 Aug;19(4):348-51 [16455543.001]
  • [Cites] Clin Neuropathol. 2005 Nov-Dec;24(6):247-51 [16320817.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):167-71 [11859971.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Sep;135(9):1239-44 [19277712.001]
  • [Cites] Clin Imaging. 1994 Oct-Dec;18(4):386-9 [8000959.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):318-24 [2056977.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):141-8 [11508813.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] J Neurosurg. 2000 Nov;93(5):887-90 [11059674.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:283-323 [11807174.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):627-37 [185169.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):227-35 [12675316.001]
  • [Cites] J Clin Neurosci. 2006 Jul;13(6):677-81 [16815020.001]
  • (PMID = 20306105.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Pyrazoles; 0 / Sulfonamides; 7GR28W0FJI / Dacarbazine; JCX84Q7J1L / Celecoxib; YF1K15M17Y / temozolomide
  •  go-up   go-down


70. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL: Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol; 2008 Aug 20;26(24):3971-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
  • PURPOSE: Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge.
  • The goal of the Children's Oncology Group (COG) AALL01P2 study was to develop a safe and active chemotherapy reinduction platform, which could be used to evaluate novel agents in future trials.
  • PATIENTS AND METHODS: One hundred twenty-four patients with ALL and first marrow relapse received three, 35-day blocks of reinduction chemotherapy: 69 with early relapse (ER; < 36 months from initial diagnosis) and 55 with late relapse (LR).
  • Minimal residual disease (MRD) was measured by flow cytometry after each treatment block.
  • RESULTS: Second complete remission (CR2) rates at the end of block 1 in 117 assessable patients were 68% +/- 6% for ER (n = 63) and 96% +/- 3% for LR (n = 54; P < .0001).
  • Five of seven patients with T-cell ALL (T-ALL) failed to achieve CR2.
  • Among patients in CR2, MRD greater than 0.01% was detected at the end of block 1 in 75% +/- 7% of ER (n = 36) versus 51% +/- 8% of LR (n = 43; P = .0375) and 12-month event-free survival was 80% +/- 7% versus 58% +/- 7% in MRD-negative versus positive patients (P < .0005).
  • Blocks 2 and 3 of therapy resulted in reduction of MRD burden in 40 of 56 patients who were MRD positive after block 1.
  • Toxicity was acceptable during all three blocks with five deaths (4%) from infections.
  • CONCLUSION: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL.
  • Alternative strategies are needed for T-ALL.
  • Serial MRD measurements were feasible and prognostic of outcome.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Sep 1;96(5):1709-15 [10961868.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):313-8 [10797352.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):3090-4 [6930318.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):470-6 [8341213.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]
  • [Cites] Blood. 1996 Aug 1;88(3):831-7 [8704238.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Pediatr Blood Cancer. 2004 Oct;43(5):571-9 [15382275.001]
  • [Cites] Haematologica. 2000 Nov;85(11 Suppl):47-53 [11268324.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [ErratumIn] J Clin Oncol. 2008 Oct 1;26(28): 4697.
  • (PMID = 18711187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA110344; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2654313
  •  go-up   go-down


71. Minton O, Stone P, Richardson A, Sharpe M, Hotopf M: Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev; 2008;(1):CD006704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (1st Quarter 2007), MEDLINE (1966 to March 2007) and a selection of cancer journals.
  • SELECTION CRITERIA: Trials were included in the review if they 1) assessed drug therapy for the management of CRF compared to placebo, usual care or a non-pharmacological intervention in 2) randomised controlled trials (RCT) of 3) adult patients with a clinical diagnosis of cancer.
  • [MeSH-major] Fatigue / drug therapy. Neoplasms / complications
  • [MeSH-minor] Central Nervous System Stimulants / therapeutic use. Hematinics / therapeutic use. Humans. Progestins / therapeutic use. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Fatigue.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2010;(7):CD006704 [20614448.001]
  • (PMID = 18254112.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Hematinics; 0 / Progestins
  • [Number-of-references] 91
  •  go-up   go-down


72. Portera CC, Gottesman RF, Srodon M, Asrari F, Dillon M, Armstrong DK: Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation. Gynecol Oncol; 2006 Jul;102(1):121-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation.
  • BACKGROUND: Central nervous system (CNS) metastases from cervical carcinoma are uncommon events.
  • No measurable disease was evident outside of the CNS.
  • Rapid progression of this patient's CNS metastatic disease suggests this form of metastases may be more aggressive and carry extremely poor prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Optic Nerve Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans


73. Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, Braziel RM: Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol; 2007 Apr;127(4):633-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1.
  • Although the pathogenesis of primary central nervous system lymphoma (PCNSL) remains unclear, it is hypothesized that specific chemokine-chemokine receptor interactions may attract malignant B lymphocytes into the CNS.
  • Tumor cells also stained positively for CXCR4.
  • [MeSH-major] B-Lymphocytes / metabolism. Brain Neoplasms / metabolism. Chemokines, CXC / biosynthesis. Lymphoma, B-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemokine CCL20. Chemokine CXCL12. Chemokines, CC / biosynthesis. Female. Humans. Immunohistochemistry. Macrophage Inflammatory Proteins / biosynthesis. Male. Middle Aged. Receptors, CXCR4 / biosynthesis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369141.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY014909
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL20 protein, human; 0 / CXCL12 protein, human; 0 / Chemokine CCL20; 0 / Chemokine CXCL12; 0 / Chemokines, CC; 0 / Chemokines, CXC; 0 / Macrophage Inflammatory Proteins; 0 / Receptors, CXCR4
  •  go-up   go-down


74. Adeolu AA: Safe surgical approach to deep pontomedullary cavernoma: an iMRI-assisted resection. Neurol India; 2005 Mar;53(1):121-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Neuronavigation. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging / methods. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805675.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


75. Vivanco-Hidalgo RM, Gimeno E, Gálvez A, Rodríguez-Campello A: [Isolated relapse in the central nervous system during cytologic and hematologic remission in a patient with acute promyelocytic leukemia]. Neurologia; 2010 Apr;25(3):200-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolated relapse in the central nervous system during cytologic and hematologic remission in a patient with acute promyelocytic leukemia].
  • [Transliterated title] Recaída aislada en el sistema nervioso central durante remisión citológica y hematológica en paciente con leucemia promielocítica aguda.
  • [MeSH-major] Brain Neoplasms / secondary. Central Nervous System / pathology. Leukemia, Promyelocytic, Acute
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Idarubicin / therapeutic use. Male. Recurrence. Remission Induction. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492869.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


76. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs; 2009 Oct;20(9):794-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
  • This retrospective study aimed to evaluate the safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with refractory or recurrent brain tumors.
  • Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1).
  • In conclusion, although intrathecal liposomal cytarabine was generally well tolerated, it should be used cautiously and only with dexamethasone prophylaxis in extensively pretreated patients with recurrent brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Neoplasms / drug therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Compassionate Use Trials. Delayed-Action Preparations. Drug Resistance, Neoplasm. Female. Humans. Infant. Injections, Spinal. Liposomes / administration & dosage. Male. Retrospective Studies. Salvage Therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617818.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


77. Dim DC, Lingamfelter DC, Taboada EM, Fiorella RM: Papillary glioneuronal tumor: a case report and review of the literature. Hum Pathol; 2006 Jul;37(7):914-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary glioneuronal tumor: a case report and review of the literature.
  • Papillary glioneuronal tumor is a recently described central nervous system neoplasm that almost always occurs adjacent to the lateral ventricle.
  • Histologic evaluation after surgical removal showed a cystic tumor consisting of 2 distinct components: a unique pseudopapillary architecture admixed with foci of solid areas.
  • The combination of cytologic benignity, lack of necrosis, and low proliferative index as evidenced by immunohistochemistry using antibody to Ki-67 confirmed the low malignant potential of this tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Papillary / pathology. Ganglioglioma / pathology
  • [MeSH-minor] Adult. Chromogranin A. Chromogranins / metabolism. Eye Injuries / complications. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Neurofilament Proteins / metabolism. S100 Proteins / metabolism. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784993.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Synaptophysin
  • [Number-of-references] 12
  •  go-up   go-down


78. Park HJ, Kim JK, Jeon HM, Oh SY, Kim SH, Nam DH, Kim H: The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells. Mol Cells; 2010 Nov;30(5):403-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neural stem cell fate determinant TLX plays a pivotal role in neurogenesis in the adult brain by maintaining neural stem cells.
  • Here, we report a tumorigenic role of TLX in brain tumor initiation and progression.
  • Ectopic expression of TLX in the U87MG glioma cell line and Ink4a/Arf-deficient mouse astrocytes (Ink4a/Arf(-/-) astrocytes) induced cell proliferation with a concomitant increase in cyclin D expression, and accelerated foci formation in soft agar and tumor formation in in vivo transplantation assays.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioma / pathology. Neoplastic Stem Cells / pathology. Neural Stem Cells / pathology. Receptors, Cytoplasmic and Nuclear / physiology
  • [MeSH-minor] Adult. Animals. Astrocytes / metabolism. Astrocytes / pathology. Astrocytoma / genetics. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Central Nervous System Neoplasms. Cyclin D / genetics. Humans. Intermediate Filament Proteins / genetics. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Nerve Tissue Proteins / genetics. Nestin. Neurogenesis. Prognosis. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mol Cells. 2011 Feb ;31(2):199. Park, Myung-Jin [removed]; Soeda, Akio [removed]
  • (PMID = 20814749.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / NR2E1 protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Cytoplasmic and Nuclear
  •  go-up   go-down


79. Stadie AT, Reisch R, Kockro RA, Fischer G, Schwandt E, Boor S, Stoeter P: Minimally invasive cerebral cavernoma surgery using keyhole approaches - solutions for technique-related limitations. Minim Invasive Neurosurg; 2009 Feb;52(1):9-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 23 cases surgery planning was done by using a virtual reality planning system, neuronavigation was used in 43 cases and the intraoperative augmented reality feature was used in 16 cases.
  • [MeSH-major] Brain Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Minimally Invasive Surgical Procedures / methods. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Endoscopy / methods. Humans. Male. Neuronavigation / methods. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19247899.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


80. LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J: A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol; 2008 Dec;63(1):109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, one patient developed grade 3 central nervous system toxicity in cycle 2 (not a DLT).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322686.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCRR NIH HHS / RR / M01 RR03186
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Neoplasm Proteins; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin
  •  go-up   go-down


81. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP: Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res; 2010 Jan 1;16(1):269-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab safety in patients with central nervous system metastases.
  • PURPOSE: Patients with central nervous system (CNS) metastases were excluded from bevacizumab trials following a case of fatal cerebral hemorrhage in a patient with hepatocellular carcinoma in 1997.
  • Safety information for bevacizumab-treated patients with CNS metastases was reviewed to determine whether general exclusion of these patients from bevacizumab treatment is still justified.
  • EXPERIMENTAL DESIGN: A retrospective exploratory analysis was conducted using datasets from 13 randomized controlled phase II/III trials (dataset A), two open-label single-arm safety trials (dataset B), and two prospective studies including patients with treated CNS metastases (dataset C).
  • In datasets A and B, known CNS metastasis was an exclusion criterion; patients with CNS metastasis had unrecognized CNS metastases at study entry or developed them during the trial.
  • All reported cerebral hemorrhage grades in patients with CNS metastases were quantified.
  • In dataset B, 321 of 4,382 patients had initially occult CNS metastases, in whom two grade 1 and one grade 3 cerebral hemorrhage (0.9%) were reported.
  • In 131 patients with treated CNS metastases in dataset C, one bevacizumab-treated patient (0.8%) developed grade 2 cerebral hemorrhage.
  • CONCLUSIONS: In this selected population, patients with CNS metastases are at similar risk of developing cerebral hemorrhage, independent of bevacizumab therapy.
  • Consequently, such patients with CNS metastases from advanced/metastatic breast cancer, non-small cell lung carcinoma, and renal and colorectal cancer should not be generally excluded from bevacizumab therapy or clinical trials.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / secondary. Cerebral Hemorrhage / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028762.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


82. O'Gara PT, Shepard JA, Yared K, Sohani AR: Case records of the Massachusetts General Hospital: Case 39-2009--a 28-year-old pregnant woman with acute cardiac failure. N Engl J Med; 2009 Dec 17;361(25):2462-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Brain / pathology. Diagnosis, Differential. Fatal Outcome. Female. Heart Failure / etiology. Humans. Lymphoma / diagnosis. Pleural Effusion / ultrasonography. Pregnancy. Pregnancy Complications, Cardiovascular / etiology. Pregnancy Trimester, Third

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20018968.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Warnke PC, Timmer J, Ostertag CB, Kopitzki K: Capillary physiology and drug delivery in central nervous system lymphomas. Ann Neurol; 2005 Jan;57(1):136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capillary physiology and drug delivery in central nervous system lymphomas.
  • To evaluate whether the chemosensitivity of primary central nervous system lymphomas to water-soluble drugs could result from improved drug delivery, we quantitatively assessed pharmacokinetic factors in seven patients.
  • The capillary permeability surface product was found to be significantly increased in central nervous system lymphomas compared with glioblastoma multiforme, medulloblastomas, and metastases.
  • Our results suggest favorable pharmacokinetics to water- and lipid-soluble drugs in primary central nervous system lymphomas.
  • [MeSH-major] Capillaries / physiopathology. Central Nervous System Neoplasms / physiopathology. Lymphoma / physiopathology. Regional Blood Flow / physiology
  • [MeSH-minor] Adult. Aged. Brain Mapping. Contrast Media / administration & dosage. Drug Delivery Systems. Female. Humans. Image Processing, Computer-Assisted / methods. Iopamidol / administration & dosage. Male. Middle Aged. Models, Theoretical. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622544.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


84. Abbott MA, Nathanson KL, Nightingale S, Maher ER, Greenstein RM: The von Hippel-Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma. Am J Med Genet A; 2006 Apr 1;140(7):685-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Von Hippel-Lindau (VHL) disease is a heritable tumor susceptibility syndrome caused by germline mutations in the VHL gene.
  • The types of tumor that can occur in affected individuals include retinal and central nervous system hemangioblastoma, renal cell carcinoma, pheochromocytoma, and others.
  • The pattern of tumor types that develops in a VHL-affected family defines the clinical subtype (1, 2A, 2B, 2C).
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Germ-Line Mutation. Pheochromocytoma / pathology. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease / genetics
  • [MeSH-minor] Adolescent. Adult. Child. DNA Mutational Analysis. Female. Genotype. Humans. Male. Middle Aged. Mutation, Missense. Pedigree. Phenotype


85. Rasmussen A, Nava-Salazar S, Yescas P, Alonso E, Revuelta R, Ortiz I, Canizales-Quinteros S, Tusié-Luna MT, López-López M: Von Hippel-Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma. J Neurosurg; 2006 Mar;104(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Central nervous system (CNS) hemangioblastomas are benign vascular tumors arising either sporadically or as a manifestation of von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome.
  • The authors studied a series of patients with CNS hemangioblastomas and their families to identify germline mutations in the VHL tumor suppressor gene and to establish a predictive testing and screening protocol.
  • All asymptomatic mutation carriers underwent genetic counseling and tumor surveillance.
  • Seven of the families had definite clinical criteria of VHL disease, five had sporadic hemangioblastoma, and four had CNS hemangioblastoma combined with minor visceral signs.
  • CONCLUSIONS: Genetic testing for mutations in the VHL gene is crucial in patients with CNS hemangioblastoma.
  • [MeSH-minor] Adolescent. Adult. Cerebellar Neoplasms. Child. Child, Preschool. DNA Mutational Analysis. Female. Genetic Testing. Humans. Male. Mexico. Middle Aged. Pedigree. Prognosis

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572651.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Ozkaynak MF, Sahdev I, Gross TG, Levine JE, Cheerva AC, Richards MK, Rozans MK, Shaw PJ, Kadota RP: A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study. J Pediatr Hematol Oncol; 2008 Mar;30(3):204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
  • Melphalan, carboplatin, etoposide +/- cyclophosphamide is a commonly used preparatory regimen in pediatric solid tumor HSCT.
  • Thirty-two patients with a variety of pediatric solid tumors were studied.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Amifostine / administration & dosage. Amifostine / adverse effects. Bone Marrow Transplantation. Bone Neoplasms / diagnosis. Bone Neoplasms / therapy. Carboplatin / administration & dosage. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Etoposide / administration & dosage. Feasibility Studies. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Humans. Hypocalcemia / chemically induced. Hypocalcemia / pathology. Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Melphalan / administration & dosage. Neuroblastoma / diagnosis. Neuroblastoma / therapy. Pilot Projects. Recurrence. Risk Factors. Sarcoma / diagnosis. Sarcoma / therapy. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome. Wilms Tumor / diagnosis. Wilms Tumor / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376282.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; Q41OR9510P / Melphalan
  •  go-up   go-down


87. Morris EB, Li C, Khan RB, Sanford RA, Boop F, Pinlac R, Xiong X, Merchant TE: Evolution of neurological impairment in pediatric infratentorial ependymoma patients. J Neurooncol; 2009 Sep;94(3):391-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Infratentorial ependymoma is a common central nervous system tumor of childhood and in patients >1 year of age is treated with maximally feasible surgical resection and radiotherapy.
  • Because of this tumor typically arises within the 4th ventricle and can invade the brainstem, patients are at risk for significant neurological impairment.

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):892-9 [18395355.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Mar;20(2):89-101 [12554520.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1347-51 [12663725.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1149-51 [1253128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):727-36 [7287533.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):304-10 [2355890.001]
  • [Cites] Arch Dis Child. 1990 Dec;65(12):1356-63 [2270944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):781-7 [7960979.001]
  • [Cites] J Child Neurol. 1995 May;10(3):209-12 [7642890.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] J Neurooncol. 1999 Jan;41(1):47-53 [10222422.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7143-51 [16192598.001]
  • [Cites] Contemp Clin Trials. 2006 Jun;27(3):269-73 [16388989.001]
  • [Cites] J Ky Med Assoc. 1999 Oct;97(10):465-71 [10544553.001]
  • (PMID = 19330288.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / P30 CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS105709; NLM/ PMC2731005
  •  go-up   go-down


88. Volikas Z, Chatzidakis EM, Condilis N, Lypiridis S, Simopoulos K: Multiple meningiomas induced by cranial irradiation. Ann Ital Chir; 2006 Jul-Aug;77(4):359-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of radiation in the induction of central nervous system tumours has repeatedly been documented.
  • [MeSH-major] Meningioma / etiology. Neoplasms, Radiation-Induced
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139969.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


89. Colović R, Micev M, Radak V, Grubor N, Colović N, Latincić S: [Stromal tumour of duodenal autonomous nerves (plexosarcoma)]. Srp Arh Celok Lek; 2007 May-Jun;135(5-6):330-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a very rare case of gastrointestinal stromal tumour (plexosarcoma) of the third and fourth portion of the duodenum, 130 x 98 x 87 mm in diameter, arising from its back wall, with central necrosis of the well circumscribed tumour, which communicated with the duodenum through an ulceration of 15 x 7mm in diameter, spreading towards the great vessels of the retroperitoneum.
  • [MeSH-major] Autonomic Nervous System Diseases / pathology. Duodenal Neoplasms / pathology. Gastrointestinal Stromal Tumors / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Duodenum / innervation. Female. Humans


90. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A: Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer; 2008 Apr 15;112(8):1812-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
  • BACKGROUND: This retrospective, single-center study assessed the feasibility, outcome, and late side effects of the treatment of immunocompetent patients with primary central nervous system lymphoma (PCNSL) at the authors' institution.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Disease Progression. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


91. Lin XB, Zhou NN, Li S, Cai QQ, Xia ZJ, Liao H, Gao Y, Huang HQ: [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients]. Ai Zheng; 2008 Oct;27(10):1100-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Methotrexate (MTX) Concentration of higher than minimal therapeutic level in cerebrospinal fluid (CSF) is essential for the therapeutic effects on central nervous system(CNS) lymphoma.
  • This study was to evaluate the effect of duration of venous infusion of high-dose MTX (HD-MTX) on drug levels in CSF, and to define the optimal schedule of HD-MTX infusion with high efficiency and low toxicity in CNS lymphomas.
  • CSF levels of MTX were much higher in the patients with CNS involvement than in those without CNS involvement.
  • CONCLUSION: The shorter duration (6 h) of MTX administration is thought to be more beneficial on the aspects of reducing toxicity and enhancing CNS pharmacokinetics.
  • [MeSH-major] Antimetabolites, Antineoplastic / cerebrospinal fluid. Central Nervous System Neoplasms / cerebrospinal fluid. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Methotrexate / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Mucositis / chemically induced. Retrospective Studies. Young Adult

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18851792.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Fujisawa H, Hasegawa M, Ueno M: Clinical features and management of five patients with supratentorial subependymoma. J Clin Neurosci; 2010 Feb;17(2):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subependymoma is a rare low-grade glioma of the central nervous system that is often asymptomatic and discovered incidentally.
  • All tumors developed supratentorially around the foramen of Monro, and their diameters ranged from 18 mm to 90 mm.
  • Of the three symptomatic patients, one presented with sudden loss of consciousness despite having only a small tumor, while in contrast, another patient showed only gradual memory disturbance despite having a very large tumor (90 mm diameter).
  • We concluded that as surgery is the only curative treatment for subependymoma, and even a small tumor can present with sudden deterioration, we recommend early and total resection.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricles / pathology. Glioma, Subependymal / diagnosis. Lateral Ventricles / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Asian Continental Ancestry Group. Cerebral Ventriculography. Consciousness Disorders / etiology. Female. Humans. Hydrocephalus / diagnosis. Hydrocephalus / etiology. Hydrocephalus / surgery. Japan. Magnetic Resonance Imaging. Male. Memory Disorders / etiology. Middle Aged. Neurosurgical Procedures. Retrospective Studies. Sex Distribution. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy

  • Genetic Alliance. consumer health - Subependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20036555.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


93. Bourdeaut F, Fréneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Couturier J, Pierron G, Sainte-Rose C, Bergeron C, Bouvier R, Rialland X, Laurence V, Michon J, Sastre-Garau X, Delattre O: hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol; 2007 Feb;211(3):323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system and peripheral RTs have been associated with biallelic inactivation of the hSNF5/INI1/SMARCB1 (hSNF5/INI1) tumour suppressor gene.
  • [MeSH-major] Biomarkers, Tumor / analysis. Chromosomal Proteins, Non-Histone / analysis. DNA-Binding Proteins / analysis. Kidney Neoplasms / diagnosis. Rhabdoid Tumor / diagnosis. Transcription Factors / analysis
  • [MeSH-minor] Adult. Carcinoma / diagnosis. Carcinoma / genetics. Child, Preschool. Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / genetics. DNA Mutational Analysis. Female. Gene Deletion. Genetic Markers. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Infant. Keratins / analysis. Male. Point Mutation. Retrospective Studies. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17152049.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / SMARCB1 protein, human; 0 / Transcription Factors; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


94. Serefhanoglu S, Haznedaroglu IC, Goker H, Buyukasik Y, Ozcebe OI: Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma. Onkologie; 2009 Nov;32(11):662-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma.
  • Central nervous system involvement was treated with craniospinal irradiation and intrathecal chemotherapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Immunoglobulin lambda-Chains / blood. Multiple Myeloma / blood. Multiple Myeloma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bone Marrow Neoplasms / diagnosis. Humans. Male


95. Kjaer TK, Hansen J: Cancer incidence among large cohort of female Danish registered nurses. Scand J Work Environ Health; 2009 Dec;35(6):446-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By record linkage, we reconstructed information on employment since 1964 using data from a national pension fund; information on vital status and reproduction was obtained from the Central Population Register.
  • RESULTS: We documented 8410 cancers during follow-up and found significantly increased SIR for breast cancer (SIR 1.1, 95% CI 1.1-1.2), cancers of the brain and nervous system (SIR 1.2, 95% CI 1.1-1.3), melanoma (SIR 1.2, 95% CI 1.1-1.3), and other skin cancers (SIR 1.2, 95% CI 1.1-1.2).
  • Nurses who were accredited by the Association after 1981 had significantly increased risks for thyroid cancer (SIR 1.9, 95% CI 1.3-2.5) and cancers of the brain and nervous system (SIR 1.5, 95% CI 1.2-1.9).
  • The elevated risks for cancers of the breast, brain, nervous system, and thyroid warrant further study.
  • [MeSH-major] Neoplasms / epidemiology. Nurses
  • [MeSH-minor] Adult. Breast Neoplasms / epidemiology. Denmark / epidemiology. Female. Humans. Incidence. Male. Melanoma / epidemiology. Occupational Exposure. Skin Neoplasms / epidemiology. Thyroid Neoplasms / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806273.001).
  • [ISSN] 0355-3140
  • [Journal-full-title] Scandinavian journal of work, environment & health
  • [ISO-abbreviation] Scand J Work Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Finland
  •  go-up   go-down


96. Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T: Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol; 2008 Jan;86(2):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
  • Treatment for patients with refractory or relapsed primary CNS lymphoma (PCNSL) remains unsatisfactory.
  • All 15 patients had measurable, contrast-enhancing tumor on cranial MRI at the time of relapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Topotecan / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome


97. Villano JL, Virk IY, Ramirez V, Propp JM, Engelhard HH, McCarthy BJ: Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis. Neuro Oncol; 2010 Mar;12(3):257-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of central nervous system germ cell tumors: nonpineal analysis.
  • Central nervous system (CNS) germ cell tumors (GCT) have not been epidemiologically well described.
  • Our study describes 2 population-based series of nonpineal CNS GCT.
  • Data on all primary (malignant and nonmalignant) CNS (ICD-O-3 sites: C70.0-C72.9, C75.1-C75.3) GCT diagnosed between 2000 and 2004 from the Central Brain Tumor Registry of the United States (CBTRUS) and on all malignant GCT diagnosed between 1992 and 2005 from the Surveillance, Epidemiology, and End Results (SEER) were analyzed.
  • For children and young adults, most tumors were malignant (86.8% and 89.0%, respectively), whereas for adults, more than half were nonmalignant (56.8%).
  • In SEER, the frequency of malignant GCT in the CNS (2.5%) was greater than that in the mediastinum (2.1%).
  • Of 408 malignant CNS GCT, 216 (52.9%) were nonpineal.
  • Overall relative survival for nonpineal CNS malignant GCT was 85.3% at 2 years, 77.3% at 5 years, and 67.6% at 10 years.
  • Nonpineal CNS GCT show no significant gender preference, yet have outcomes similar to pineal GCT.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Registries. SEER Program. United States / epidemiology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):121-30 [18287340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7268-76 [11585765.001]
  • [Cites] Int J Clin Oncol. 2001 Aug;6(4):183-91 [11706556.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):115-22 [11908867.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):487-500 [12354131.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):126-33 [15236278.001]
  • [Cites] Am J Clin Pathol. 1976 Apr;65(4):450-4 [178171.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):43-9 [3034798.001]
  • [Cites] J Neurosurg. 1987 Jul;67(1):65-70 [2439668.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5):1039-44 [2476011.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):231-41 [2156245.001]
  • [Cites] Chest. 1991 Feb;99(2):472-9 [1846573.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Dec;5(6):1189-209 [1663939.001]
  • [Cites] Radiat Med. 1992 Mar-Apr;10(2):55-61 [1320768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] Med Pediatr Oncol. 1995 Jun;24(6):368-72 [7536294.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] Childs Nerv Syst. 1999 Mar;15(2-3):119-26; discussion 127 [10230668.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):133-7 [10413166.001]
  • [Cites] Bull N Y Acad Med. 1950 Jul;26(7):440-60 [15426876.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):524-30 [16383251.001]
  • [Cites] Obstet Gynecol. 2006 May;107(5):1075-85 [16648414.001]
  • [Cites] Urology. 2006 Aug;68(2):402-5; discussion 405 [16904461.001]
  • [Cites] Neurology. 2007 May 15;68(20):1668-73 [17502547.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):71-8 [17906866.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):71-6 [10582672.001]
  • (PMID = 20167813.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940596
  •  go-up   go-down


98. Tzekov C, Spiriev T, Cherninkova S, Bussarsky V, Laleva L, Cekov A, Naydenov E, Minkin K, Marinov M, Romansky K: [Characteristics and prognosis of visual deficit caused by parasellar meningiomas]. Khirurgiia (Sofiia); 2010;(2-3):19-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common slow growing tumors of the central nervous system which arise from the arachnoid cells.
  • One certain group of them--tuberculum sellae (TS), cavernous sinus (CS), anterior clinoid (AC), and planum sphenoidale (PS) meningiomas, a group often called "parasellar", present with monocular or binocular visual deterioration, which is often unrecognized by patients until visual loss is severe and the tumor has reached a significant size.
  • AIM: To describes the type of visual deficit, severity of the symptoms and surgical treatment of tumors with the above mentioned localization.
  • Close collaboration between different specialists (ophthalmologists, neurologist and neurosurgeons) is essential for treatment of these tumors and prevention of the visual deterioration.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningeal Neoplasms / surgery. Meningioma / complications. Meningioma / surgery. Vision Disorders / diagnosis. Vision Disorders / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Bulgaria. Child. Eye / pathology. Female. Humans. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Retrospective Studies. Visual Acuity. Young Adult

  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21972690.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


99. Alécio-Mattei T, Alécio-Mattei J, Aguiar PH, Ramina R: Primary central nervous system lymphomas in immunocompetent patients. Neurocirugia (Astur); 2006 Feb;17(1):46-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas in immunocompetent patients.
  • OBJECTIVES: Primary central nervous system lymphoma (PCNSL) is a rare pathology and is most often seen in immunodeficient patients.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunocompetence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565780.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 32
  •  go-up   go-down


100. Lee Y, Kim JH, Kim E, Park SH, Yim YJ, Sohn CH, Chang KH: Tumor-mimicking primary angiitis of the central nervous system: initial and follow-up MR features. Neuroradiology; 2009 Oct;51(10):651-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-mimicking primary angiitis of the central nervous system: initial and follow-up MR features.
  • INTRODUCTION: Primary angiitis of the central nervous system (PACNS) is an extremely rare vasculitis of unknown etiology.
  • The purpose of this study was to describe the initial and follow-up magnetic resonance (MR) imaging features of the tumor-mimicking PACNS.
  • METHODS: We retrospectively reviewed a total of 21 initial and follow-up brain MR images obtained in four patients with biopsy-proven PACNS mimicking brain tumor on MR images during the periods from 1 to 8.1 years.
  • CONCLUSION: Tumor-mimicking PACNS shows variable features on initial MR images but shows good responses to appropriate immunosuppressive therapy on follow-up MR images.
  • [MeSH-major] Brain / pathology. Vasculitis, Central Nervous System / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Cerebral Angiography. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Female. Follow-Up Studies. Humans. Immunosuppression. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Angiography. Magnetic Resonance Spectroscopy. Male. Protons. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Oct;107(4):873-7 [17937238.001]
  • [Cites] Neurology. 1997 Dec;49(6):1696-9 [9409370.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):192-9 [16418382.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1732-5 [18625623.001]
  • [Cites] J Neurol. 1984;231(1):38-42 [6716109.001]
  • [Cites] Neuroradiology. 2007 Jun;49(6):471-9 [17345075.001]
  • [Cites] Australas Radiol. 2003 Jun;47(2):127-34 [12780440.001]
  • [Cites] Neurology. 1995 Sep;45(9):1731-4 [7675235.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):87-9 [9974061.001]
  • [Cites] Cleve Clin J Med. 1992 May-Jun;59(3):293-306 [1516217.001]
  • [Cites] Neuroradiology. 2001 Aug;43(8):599-607 [11548164.001]
  • [Cites] Ann Neurol. 2007 Nov;62(5):442-51 [17924545.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Mar;26(3):642-5 [15760879.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Feb;15(2):317-30 [8192080.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):75-85 [9974060.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):595-603 [18240248.001]
  • [Cites] Neurology. 1995 Aug;45(8):1462-5 [7644041.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Oct;23(9):1561-3 [12372748.001]
  • [Cites] Radiology. 1992 Jan;182(1):65-72 [1727311.001]
  • [Cites] Surg Neurol. 1989 Jan;31(1):49-53 [2645673.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):164-71 [1740300.001]
  • (PMID = 19529928.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Protons
  •  go-up   go-down






Advertisement